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Abstract
Schizophrenia is a chronic and debilitating psychiatric illness affecting approximately 1% of the world's
population for which there is no cure and treatment options are limited. Poor understanding of disease
pathology and the difficulty in modeling psychiatric symptoms in animal models has hindered the search
for a cure. Despite these difficulties great progress has been made on several fronts. Genetic studies have
identified risk genes for disease, while fMRI and histology experiments have located brain regions with
altered activity and cytoarchitecture. Pharmacology, molecular and immunology studies have identified
receptor signaling pathways that are perturbed as well.
One of the biggest challenges currently facing the field is elucidating the mechanisms linking genetic and
environmental risk to the altered processes observed in the brains of schizophrenic patients. One
approach to this question may be to investigate the postmortem brain tissues of patients. The goal of this
thesis is to use mass spectrometry based proteomics to investigate the expression and partitioning of
postsynaptic density proteins in these tissues. The postsynaptic density is implicated in disease
pathology by genetic, cytoarchitecture and molecular studies. Thus, there is a good possibility that its
protein composition reflects the crossroads of genetic risk and dysregulated molecular and
developmental processes.
A qualitative analysis of the human postsynaptic density was performed to catalog the proteins therein.
Data from this experiment was harnessed to develop a mass spectrometry method for the targeted
quantification of over 200 synaptic proteins. This method was then used to validate subcellular
fractionation of human postmortem brain tissue to capture synaptic microdomains. Finally, this targeted
mass spectrometry method was utilized to quantify synaptic protein expression and PSD partitioning in
postmortem brain tissues of subjects and patients. The enrichment of PSD proteins was elevated in
tissue from schizophrenic subjects compared to controls, while total protein expression was unaltered.
This data suggests that partitioning, not expression, of postsynaptic proteins is altered in schizophrenia.
The results of this study demonstrate the power of a targeted mass spectrometry approach and provide
an important context in which to study the dysregulation of synaptic processes in schizophrenia.
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ABSTRACT
TARGETED PROTEOMICS AND BIOCHEMICAL FRACTIONATION:
NEW TOOLS FOR DECIPHERING THE SYNAPSE IN SCHIZOPHRENIA
Matthew L. MacDonald
Advisors:
Chang-Gyu Hahn
Ian A. Blair
Schizophrenia is a chronic and debilitating psychiatric illness affecting
approximately 1% of the world’s population for which there is no cure and treatment
options are limited. Poor understanding of disease pathology and the difficulty in
modeling psychiatric symptoms in animal models has hindered the search for a cure.
Despite these difficulties great progress has been made on several fronts. Genetic studies
have identified risk genes for disease, while fMRI and histology experiments have
located brain regions with altered activity and cytoarchitecture. Pharmacology, molecular
and immunology studies have identified receptor signaling pathways that are perturbed as
well.
One of the biggest challenges currently facing the field is elucidating the
mechanisms linking genetic and environmental risk to the altered processes observed in
the brains of schizophrenic patients. One approach to this question may be to investigate
the postmortem brain tissues of patients. The goal of this thesis is to use mass
spectrometry based proteomics to investigate the expression and partitioning of
postsynaptic density proteins in these tissues. The postsynaptic density is implicated in
disease pathology by genetic, cytoarchitecture and molecular studies. Thus, there is a
good possibility that its protein composition reflects the crossroads of genetic risk and
dysregulated molecular and developmental processes.

v

A qualitative analysis of the human postsynaptic density was performed to catalog
the proteins therein. Data from this experiment was harnessed to develop a mass
spectrometry method for the targeted quantification of over 200 synaptic proteins. This
method was then used to validate subcellular fractionation of human postmortem brain
tissue to capture synaptic microdomains. Finally, this targeted mass spectrometry method
was utilized to quantify synaptic protein expression and PSD partitioning in postmortem
brain tissues of subjects and patients. The enrichment of PSD proteins was elevated in
tissue from schizophrenic subjects compared to controls, while total protein expression
was unaltered. This data suggests that partitioning, not expression, of postsynaptic
proteins is altered in schizophrenia. The results of this study demonstrate the power of a
targeted mass spectrometry approach and provide an important context in which to study
the dysregulation of synaptic processes in schizophrenia.
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CHAPTER ONE
GENERAL INTRODUCTION

1

1. Schizophrenia
Schizophrenia (SCZ) is a chronic and debilitating psychiatric illness affecting
approximately 1% of the world’s population1, 2. Disease etiology is not currently
understood, and while some symptoms can be controlled with therapeutics, no cure
exists.
SCZ has broad diagnostic criteria and is defined by cognitive, sensory and
emotional disturbances of mind. Schizophrenia-diagnosed mathematician Dr. John Nash
described his experience with the disease thus:
“…I started to think I was a man of great religious importance, and to hear voices
all the time. I began to hear something like telephone calls in my head, from
people opposed to my ideas. ...The delirium was like a dream from which I
seemed never to awake.”3
SCZ symptoms are multilayered, and can be divided into three groups for research
purposes: 1) positive symptoms, 2) negative symptoms and 3) cognitive symptoms.
Positive symptoms are disturbances of perception and thought content, making it difficult
for patients to interpret or accurately compare their own beliefs to reality. Typical
manifestations include hallucinations (often auditory), along with delusions and chaotic
thinking (inability to organize thoughts and associations), which often results in bizarre
behavior and speech. Negative symptoms include alogia, apathy and anhedonia, which
can compromise the ability to perform normal social behaviors4, 5. Patients can withdraw
socially, lack the ability to feel or express emotion and have difficulty communicating.
Cognitive symptoms encompass impairments in working memory and executive function.
This final class is usually the most consistent over time, persisting even when positive
and negative symptoms are controlled or absent.
Disease onset typically occurs in the age range of the late teens to early twenties,
with women having a later average onset age as compared to men1, 2. A “prodromal”
period, categorized by cognitive decline, along with mild positive and negative
symptoms, typically precedes full emergence of disease symptoms6. However, many
prodromal symptoms overlap with other psychiatric diseases, as well as with normal
adolescent affects. Thus, they are not predictive and often only diagnostically helpful in
2

retrospect7. Additionally, the full array of disease symptoms do not usually present
simultaneously. Positive and negative symptoms can fluctuate in intensity, while
cognitive symptoms tend to be more consistent. After the first interaction with a
psychiatrist, months or even years can be required to establish the pattern and persistence
required for an accurate diagnosis. For those who have been diagnosed with SCZ, the
long-term outlook points toward an arduous track. Only 30% of those diagnosed with
SCZ are able live without assistance, 6% are homeless, 6% are incarcerated and 15% will
commit suicide89.
While therapeutic agents can control some of the symptoms, there is no cure for
the disease. Positive symptoms are the most likely to respond to pharmacologic
intervention, while negative symptoms are less responsive and cognitive symptoms are
largely resistant to intervention. Complicating pharmacologic interventions are the severe
side effects that can accompany therapeutics, which patients often find intolerable.
Examples of such side effects include tardive dyskinesia, which can arise as a side effect
of high potency typical neuroleptics, and weight gain, which can be a side effect of some
atypical neuroleptics. The presence of severe side effects is notable in that they can
contribute to medication non-compliance and recurrent hospitalization 10, 11.
SCZ has been demonstrated to have a strong genetic component12, 13, with 50% of
monozygotic twins and 6-17% of first-degree relatives sharing the disease14.
Additionally, a variety of environmental factors, including exposure to infectious,
autoimmune, toxic, nutritional, or traumatic insults during pre- and/or postnatal
development, have been proposed as contributing factors accounting for a portion of what
cannot be explained by genetics alone15. Current theories of disease etiology postulate
that genetic vulnerabilities and environmental insults converge to impair multiple brain
circuits during development, manifesting full disease symptoms almost two decades into
life.
2. Schizophrenia is a disease of mind
SCZ is a disease of mind. In his autobiography In Search of Memory, Nobel
laureate Dr. Eric Kandel described mind as:
3

“… a set of
operations carried
out by the brain,
much as walking
is a set of
operations carried
out by the legs,
except
dramatically more
complex.”16
In the brain,
neural circuits
connecting
different regions
carry out the
operations. To

Figure 1-1. Relevant brain areas in schizophrenia. The diverse
symptoms of schizophrenia implicate multiple brain areas and circuits.
The prefrontal cortex receives and sends to/from many of these brain
areas. These areas, their connections, functions and associated
symptoms are depicted.

investigate a disease of mind is to study the biology of the underlying brain regions and
circuits that perform disturbed operations. The multiple dimensions of mental operations
perturbed in SCZ suggest that several brain regions and circuits are involved, likely in a
complex manner. Advances in neuroimaging technologies, most notably functional
magnetic resonance imaging (fMRI), have allowed researchers to look into the active
brain, while histological techniques have made it possible to investigate neuronal
cytoarchitecture in the postmortem brain tissues of patients. Using these techniques,
skilled and dedicated researchers have linked specific brain areas to certain disease
features, and cataloged neuroanatomical irregularities. Figure 1-1 depicts several brain
areas that have been implicated in SCZ, their suggested relationships to particular
symptoms and anatomical findings in diseased tissue.
2.1

Cognitive symptoms are a core feature of disease
Although positive symptoms tend to be more prominent, cognitive symptoms are

more persistent and difficult to treat. Cognitive symptoms are observed in a majority of
patients, present independently from psychotic symptoms17, and are endure throughout
4

the lifespan18-21. Additionally, milder cognitive deficits can be observed in non-SCZ
relatives22, suggesting a genetic link, which is expanded on further below. Finally,
cognitive symptom severity is a strong predictor of poor functional recovery17, 23. Thus,
cognitive symptoms are now considered to be a core feature of the disease.
Working memory, the ability to transiently maintain and process information, and
executive function, the coordination of different brain areas and neural processes to guide
thoughts and actions, are the most intensely studied of the cognitive symptoms. More
than any other brain region, the prefrontal cortex (PFC) is thought to be the primary
orchestrator of these functions24.
2.2

The prefrontal cortex is the seat of executive function.
The PFC is the anterior section of the frontal lobes, and is responsible for

heterogeneous mental functions. It can also be defined as the area of the cerebral cortex
that receives inputs from the thalamic mediodorsal nucleus. In primates, the PFC is
differentiated from the rest of the frontal cortex by the presence of a well-developed
granular layer 4. PFC size distinguishes humans within the primate family, representing
29% of the total human cortex, while comprising only 17% in chimps and 11.5% in
macaques25 24. The general cytoarchitecture of the PFC is similar to that of other cortical
regions, consisting of stratified layers of cells with regular and systematic connections
(Figure 1-2). Within this basic template, the PFC is architecturally diverse. Broadmann
used classical histological techniques to identify 10 distinct regions, and modern
techniques have identified further anatomical diversity within these areas. The PFC
receives inputs from a wide variety of brain areas, most notably the thalamus, brain stem
tegmentum, amygdala, hippocampus, cingulate cortex, cerebellum, locus coeruleus,
ventral tegmental area and the raphe. In turn, the PFC extends projects to multiple
structures, including the thalamus, hippocampus and other cortical regions. The PFC is
also extensively connected to the motor and sensory cortices24. The PFC is therefore, a
demonstrably vital hub for motor, spatial, memory, internal state and emotional
information

5

Figure 1-2. Dorsolateral prefrontal cortex cytoarchitecture and NMDA receptor
signaling is perturbed in schizophrenia. A. “an unstained coronal block cut immediately
anterior to the corpus callosum through the left hemisphere of a postmortem human brain.” –
Lewis et al. 200843. B, Cortical layers and two basic neuron types. 1. GABAergic inhibitory
neurons synapse locally within the cortex to regulated and coordinate pyramidal neuron
activity. 2. Excitatory glutamatergic pyramidal neurons represent 75% of the neuronal
population of the DLPFC. Pyramidal neuron dendrites receive information locally and project
axons to other cortical areas, the striatum or thalamus, depending on the layer. The majority of
layer 2 and 3 pyramidal neurons project to other cortical areas. C. Dendritic spine density is
decreased in layers 2 and 3 of the DLPFC in schizophrenia35, 43. 3, depicts a dendrite in a
normal subject and 4, a dendrite in a schizophrenia subject. D, depicts some of the major PSD
proteins58 and recent findings from the Hahn lab84 of altered protein-protein interactions and
signaling. 5. NRG1 induced activation of ErbB4 is increased as is ErbB4 – PSD95 – NR
association in schizophrenia (6.). 7. NMDA/glycine induced NR activation is decreased in
schizophrenia, while ErbB4 attenuation of NR activation is increased. As PSD95 complexes
ErbB4 to NR and PSD95 – ErbB4 association is required for ErbB4 activation; these results
suggest that altered protein composition or interactions at the PSD could contribute to NR
hypofunction in schizophrenia. 8. src kinase activity is decreased in schizophrenia as well,
also likely contributing to NR hypofunction.

PFC cytoarchitecture is highly organized and complex. Like all cortical areas it is
composed of stratified orders of cells with regular connective patterns (Figure 1-2).
Pyramidal cells, excitatory glutamatergic neurons, constitute 75% of these layers24.
Generally speaking, neurons in different layers project to different brain regions. Those in
layers 2 and 3 project to other cortical regions, 5 to the striatum and brain-stem, 6 to the
thalamus. Likewise, projections from other brain areas tend to target discreet layers. Most
of the other 25% of PFC neurons are inhibitory GABAergic interneurons that both
6

receive and project within the same PFC area24. Interneurons serve to coordinate
interneuron function, participating in important inhibitory feedback loops26.
Joaquin Fuster has proposed that the PFC orchestrates three executive function
processes: 1) Complex action (planning), 2) Goal-oriented behavior and 3) Executive
attention. In this theory, the PFC is thought to process information and conduct activity
from numerous other brain areas, culminating in the ability to perform executive
function. This view fits well with the findings of PFC cytoarchitecture and connections
discussed above. Thus, the PFC is a compelling target in which to study the biology of
SCZ, as a plethora of functions to which it is connected are perturbed, and the complexity
of the PFC structure mirrors the complexity of the disease. fMRI and cytoarchitectural
studies have consistently implicated three brain areas in connection with the cognitive
symptoms of SCZ: the dorsolateral prefrontal cortex (DLPFC), anterior cingulate cortex
(ACC) and hippocampus42 43. The remainder of this introduction will focus on the
DLPFC, as the studies described in the following chapters were performed using tissue
from this area of the PFC.
2.3

Altered DLPFC activation is associated with impaired working memory in
schizophrenia
Neuroimaging studies have implicated dysregulated DLPFC functioning in

connection with cognitive symptoms of SCZ. Specifically, alterations in both blood flow
and glucose utilization in the DLPFC have been observed in SCZ patients performing
working memory and executive function tasks. During low difficulty tasks, increased
DLPFC blood flow and glucose utilization have been observed, with no performance
deficits. During more difficult tasks, however, a decrease in DLPFC blood flow and
glucose utilization was observed, and performance deficits were exhibited27 28. These
performance deficits are not reliably observed during resting, and appear to be unique to
SCZ among neuropsychiatric diseases29 30.
In addition to task-dependent alteration in DLPFC activity, deficits in brain tissue
have been observed in SCZ patients. Meta-analyses of reports on grey matter volume in
SCZ indicate moderate loss in the PFC and hippocampus31 32. The combination of task7

related and grey matter deficits implicates the DLPFC in cognitive symptoms, although
the exact mechanisms underlying the connections between symptoms and anatomy are
not yet clear. However, PFC histological and molecular investigations have begun to
provide some insight into this question.
2.4

Synaptic connectivity of pyramidal neurons is decreased in schizophrenia
Three observations, repeated by several groups across different cohorts, point to

decreased synaptic connectivity, without neuronal loss, in the DLPFC, proving a
compelling explanation for decreased grey matter volume. 1) Neuropil, the connective
processes between neurons, are decreased in SCZ while the total number of neurons
appears to be unaltered33 34. 2) The dendritic spine density of pyramidal neurons, per
dendrite length, in DLPFC layers II and III is decreased in SCZ35 36. It is important to
note that decreases in dendritic spine density and neuropil are not limited to the DLPFC
and extend to other brain regions with impaired function in SCZ including the visual,
auditory and temporal cortices and the hippocampus 37-39. 3) Pyramidal neuron cell
volume and dendrite length is also decreased in SCZ in the DLPFC and other affected
brain areas. These observations are not as large or consistent as the decreases in neuropil
and spine density. Additionally, efforts to link decreased spine density to decreases in
pyramidal neuron cell volume in several brain areas in SCZ have returned modest or
insignificant correlations37 35 40 41.
To summarize the findings outlined above, pyramidal neuron dendritic spine
density is decreased in layers 2 and 3 of the DLPFC in SCZ, while the total number of
pyramidal neurons is unaltered. This decrease in spine density is per spine length and
thus is independent of decreased length or branching. Pyramidal cell volume is also
decreased to a lesser extent in these layers, but does not correlate strongly with decreased
spine density. Importantly, the few studies that have directly counted axon terminals in
cortical regions of SCZ tissues have observed a loss similar to spines37.
The fact that dendritic spine loss is observed across several cortical areas suggests
that it could represent the end point of a common pathology. The loss of synaptic
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connectivity likely explains the decrease in cortical grey mater and is widely believed to
underlie the function deficits observed in the DLPFC, and other cortical areas, of SCZ.
The number of synaptic connections, and spines, increases steadily through
development, reaching its zenith in late childhood/early adolescence and decreases
gradually through adulthood into old age6, 42. This decrease is referred to as “pruning”.
Increased pruning is one of several hypotheses put forward to explain the decreased spine
density observed in the tissues of elderly SCZ patients investigated6, 42. An alternate
hypothesis posits that synaptic numbers in SCZ patients simply never reach the amounts
present in normal individuals42. These hypotheses are difficult to test, as brain tissues
from normal children are extremely rare and SCZ diagnosed children are, for all practical
purposes, nonexistent. Never the less, both of these hypotheses hinge upon aberrant
neuroplasticity, the term that describes the broad mechanisms by which neurons form,
strengthen and prune synaptic connections. The involvement of neuroplasticity in SCZ
pathology is well supported by evidence from genetic, pharmacological, behavioral and
immunological studies. A brief primer on neuroplasticity, postsynaptic glutamate
signaling and the synaptic microdomain in which it occurs, the postsynaptic density
(PSD), is required to put this evidence in context.
3. Glutamate signaling at the postsynaptic density is an essential component of
neuroplasticity
The constant forming, strengthening and pruning of synapses in the brain are
crucial aspects of brain functioning, and are essential for learning and memory43.
Neuroplasticity describes the progression from short-term processes, such as the ligand
receptor interactions and membrane depolarization, through long term consequences, the
changes in gene expression that ultimately result in neuron and synapse structure
remodeling. Glutamate signaling is central in initiating and maintaining this process.
3.1

Glutamate receptors
Glutamate signaling is critical for the formation and maintenance of synaptic

connections in both the developing and mature brain44. Glutamate acts through
ionotropic and metabotropic receptors to mediate Ca2+ influx, which activates signal
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transduction cascades. Cascades include kinases and phosphatases that can alter the
phosphorylation state of receptors, ion channels, transcription factors and other signaling
proteins with diverse and far-reaching effects. Three families of glutamate receptors play
a role in regulating neuroplasticity.
The N-methyl-D-aspartate receptor (NR) is a slow-acting ionotropic glutamate
receptor, named for the ligand to which it selectively responds45, 46. The NR is a
heterotetramer comprised of subunits from three families: two obligate NR1 subunits, of
which there are eight splice variants, and two NR2 subunits, of which there are 4 types
(A,B,C and D)45, 47-49. The expression of alternate NR1 splice variants regulates
trafficking to the synapse50, while NR2 subunits differ in their affinity for ligand binding,
channel conductance, and downstream signaling51, 52. A third family of NR subunits
(NR3) suppresses glutamate-induced currents53.
2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl propanoic acid (AMPA) and kainite
receptors are also ionotropic receptors, composed of four subunits. AMPA receptors are
primarily postsynaptic while kainite receptors have both pre- and post-synaptic functions
(Ref). Conductance of these tetramers is determined by subunit compositions48.
Activated ionotropic glutamate receptors are permeable to Na+ and K+ and Ca2+.
NR activation requires the presence of both glutamate and glycine, as well as the absence
of Mg2+ in the channel pore. Mg2+ removal is voltage dependent, mediated by AMPA
receptor-dependent membrane depolarization. Thus, the NMDA and AMPA receptor
function together as a coincidence detector, which is believed to be central for tightly
regulating neuroplasticity54.
A third family of glutamate receptors, metabotropic glutamate receptors (mGluRs),
also have an important role in regulating glutamate release and NR activity. mGluRs are
seven transmembrane G-protein coupled receptors. Eight subtypes and three family
groupings have been identified. Group I mGluRs (mGluR1 and mGluR5) activate the
production of cyclic AMP and arachidonic acid via phospholipase C (PLC)55, while
group II (mGLuR2 and 3) and group III (mGluRs 4,6,7 and 8) inhibit adenylate cyclase
activity. Postsynaptic mGluRs can impact neuroplastic signaling cascades by regulating
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the release of intracellular calcium stores. Additionally, group I mGluRs are complexed
to the NR, with the ability to regulate its activity and permeability56, 57.
In summary, diverse receptor families with robust interactions mediate glutamate
activation of neuroplasticity. Signaling molecules and scaffolding proteins facilitate
receptor interactions in the postsynaptic density (PSD)58.
3.2

The postsynaptic Density
The postsynaptic density (PSD) is a thickening of the dendritic membrane,

sometimes considered to be an “open organelle”58. The PSD is rich in glutamate
receptors, as well as scaffolding proteins and kinases (Figure 1-2)58. Here, interactions
and signaling events proceed in a complicated, non-linear fashion to integrate the pre-,
post- and extra-synaptic signaling events described above that regulate the
neuroplasticity-defining transcription, translation and protein trafficking events as well as
cytoskeletal changes44, 58-60. The PSD is a fluid, but highly organized structure. This
organization is mediated by several families of scaffolding proteins58, 59 that tether
glutamate receptors to the membrane, linking them with other receptors, channels and
signaling molecules. Several of these scaffolding proteins also have important roles in
receptor trafficking58.
4. Aberrant neuroplasticity and NMDA receptor function in schizophrenia
Several lines of evidence, from pharmacological, immunological and genetic studies
reviewed below, have convincingly linked NR hypofunction to various symptom
domains of SCZ.
4.1

Pharmacologic evidence for NMDA receptor hypofunction in schizophrenia
Pharmacological studies provided the first evidence for NR hypofunction in SCZ.

The noncompetitive NR antagonists phencyclidine (PCP) and ketamine produce positive,
negative and cognitive symptoms in normal human subjects, and exacerbate these
symptoms in SCZ subjects for prolonged periods following NMDA antagonist
administration61, 62. PCP and ketamine also induce behavioral correlates of positive and
negative symptoms in non-human primates and rodents, such as cognitive and
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sensorimotor gating impairments, hyperlocomotion and social impairments63.Importantly,
treatment with antipsychotic drugs has been demonstrated to ameliorate these
behaviors64.
Concordant with the evidence that antagonizing NR function produces the
behavioral and cytoarchitectural abnormalities observed in SCZ, agents that boost NR
functions, such as D-serine, sarcosine and N-acetyl-cysteine, have demonstrated value as
adjunct therapies65-68. Additionally, one meta-analysis of clinical trials reports that NR
function-boosting agents have exhibited efficacy in improving negative symptom
treatment outcomes when administrated alongside typical antipsychotics69.
4.2

NMDA receptor encephalopathies produce schizophrenia-like symptoms
Recent characterizations of NR encephalopathies also provide compelling

evidence for NR dysfunction in SCZ. NR autoantibodies producing a SCZ-like
syndrome in patients that is completely resolved following dialysis, provides further
supporting evidence for NR involvement in SCZ70. Furthermore, studies in rats have
demonstrated that NMDA antibodies obtained from encephalopathy patients internalize
NRs, decrease NR-mediated currents and impair learning and memory71.
4.3

Schizophrenia risk genes impact NMDA receptor and PSD signaling
Many of the most reproducibly identified SCZ risk genes are directly connected to

NR signaling at the PSD72-7677. Four well studied examples of NMDA-associated proteins
that are also risk genes include disrupted in SCZ 1 (DISC1), regulator of G-protein
signaling 4 (RGS4), neuregulin 1 (NRG1) and v-erb-a erythroblastic leukemia viral
oncogene homolog 4 (ErbB4)72, 74, 78-80 81, 82. NRG1-ErbB4 signaling attenuates NR
activity through an Src-dependent pathway83, 84. DISC1 has been shown to regulate
trafficking of NRs85 , and RGS4 attenuates mGluR5 activation, which complexes to the
NR via PSD scaffolding proteins81, 82.
From a broader standpoint, recent bioinformatics analyses of proteins identified in
human PSD enrichments and mouse immune-precipitated (IP) PSD95 complexes
revealed the presence of a significant number of risk genes for multiple neuropsychiatric
diseases relative to the total genome76, 86. Of these diseases, risk genes for SCZ were
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found to be the most significantly represented among all known risk genes for
neuropsychiatric illnesses75, 86, 87.
4.4

NMDA receptor activity and PSD signaling are perturbed in PFC tissue of
patients
The pharmacological and immunological evidence presented above strongly

suggest the involvement of NR hypofunction in SCZ symptoms. Genetic studies have
identified a number of risk genes that indirectly mediate PSD and NR activity, trafficking
and downstream signaling72, 74, 77. Many of the genetic investigations share the goal of
identifying risk genes that could explain disease symptoms and neuronal cytoarchitecture,
mediated through neuroplasticity and developmental processes. The PSD has been
repeatedly implicated in SCZ, as seen in the vast array of risk genes participating in PSD
processes, the prominent role of the PSD in NR activity regulation and the complexity of
PSD signaling processes75, 76, 86. Based on the multiplicity of PSD-related findings,
several researchers have suggested that the PSD could act as a point of convergence for
the genetic and environmental risk factors, which thereby manifest themselves impaired
neuroplasticity and resulting in the anatomic abnormalities believed to underlie disease
symptoms75, 78, 88 89. However, the NR hypofunction and PSD hub hypotheses have been
difficult to test directly in human patient tissues. Utilizing a novel ex-vivo stimulation
paradigm, our lab has investigated NR activity, downstream signaling and protein
interactions in human patient tissues.
NMDA/glycine-induced NR activation was found to be attenuated in post-mortem
PFCs of SCZ patients as assessed by three independent metrics: NR2A tyrosine
phosphorylation and recruitment of PLCγ and nNOS490. Surprisingly, MK-801 binding
capacity of synaptic membranes and NR1/PSD-95 complexes was enhanced, as was the
amount of NR1 in PSD enrichments as measured by Western Blot. NR association with
its signaling partners, phospholipase C gamma (PLCγ) and protein kinase C gamma
(PKCγ) were significantly decreased in patient PSDs. Additionally, NR mediated
activation of PKCγ, protein tyrosine kinase 2 (Pyk-2), and the tyrosine kinase Src was
also reduced in patient tissues (Banerjee et al. in review). To test if such changes in
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kinase association and activation could account in part for dysregulation of NR function
in SCZ, Src activity was assessed independent of its upstream kinases. Indeed, src
activity was significantly decreased in response to src-SH2 domain binding peptides in
the synaptic membranes of the SCZ patient group (Banerjee et al. in review).
Activity of the risk gene ErbB4 was also altered in SCZ patients. NRG1
activation of ErbB4 signaling was dramatically increased in SCZ subjects, as was NRG1ErbB4 attenuation of the NR. Interestingly, these changes were accompanied by a
significant enhancement in the association of ErbB4 with PSD-95 in SCZ subjects90.
Since coupling between ErbB4 and PSD-95 is crucial for its activation91, 92 this study
suggests that altered protein-protein interactions could contribute to altered ErbB4
signaling.
4.5

Attenuation of NMDA receptor activity reduced cortical spine density
Numerous studies have demonstrated that attenuating NR function, either directly

or through proximal proteins or pathways, can result in decreased dendritic spine density.
The complete knockdown of NR1 from pyramidal neurons in the cortex results in a 40%
decrease in spine density in layers 2 and 393. In a more subtle manipulation of NR
activity in vivo, Balu et al. demonstrated that decreased amounts of the NR co-agonist
serine (induced by serine racemase knockout) decreased cortical spine density. Decreased
amounts of the endogenous NR antagonist glycine (induced by knocking out one copy of
glycine transporter GlyT1) increased cortical spine density94.
4.6

The link between genetic risk for disease and PSD/NMDA receptor
hypofunction is implied, but has not been observed
Pharmacological, behavioral and immunological studies have demonstrated that

attenuation of NR function produces a variety of SCZ-like symptoms in humans and their
behavior corollaries in animals. Transgenic studies in mice have demonstrated that both
extreme complete loss and subtle attenuation of NR function can mimic the decreased
spine density observed in SCZ. The ex-vivo stimulation experiments performed in the
Hahn lab directly observed NR hypofunction the tissues of SCZ patients. Together these
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studies powerful evidence that NR hypofunction can acutely induce SCZ like symptoms
and impact neuronal development resulting in dendritic spine loss.
Genetic studies have identified a SCZ risk genes, many of which are directly
involved in NR and PSD signaling. The elucidation of these genes provides a roadmap in
which genetic insults would converge on PSD signaling, impairing synaptic plasticity,
resulting in the decreased spine density that is linked to SCZ symptoms. Unfortunately,
this body of work does not provide information as to how genetic risk genes converge to
dysregulate NR function. For example, increased NRG1-ErbB4 attenuation of NR in SCZ
tissue provides a concrete link between the activity of a risk gene products and NR
hypofunction at the postsynaptic density. But, genetic variation in ErbB4 can realistically
account for only a small fraction of SCZ cases. Indeed, genetic variation in ErbB4 cannot
even explain ErbB4 hyperactivity in SCZ.
While the studies described above have made great strides in uncovering the
genetic risk factors and perturbed neuronal systems that ultimately result in SCZ
symptoms, the mechanism by which genetic risk factors set in motion these perturbations
is currently unknown. Thus, recent studies into SCZ pathology have focused on this
question, searching for molecular correlates that can link risk genes, NR hypofunction
and decreased spine density. All three of these lines of evidence predict that such
correlates should exist, but concrete observations have proven elusive. The next section
discusses this conundrum in more detail.
5. Molecular correlates of genetic risk and reduced spine density are elusive
The loss of neuropil in the DLPFC of SCZ, specifically decreased dendritic spine
density, may predict alterations in pre- and post-synaptic microdomains and a paralleled
decrease in PSD proteins. Likewise, a likely point of convergence for genetic risk factors
to exert their effect on NR function and synaptic plasticity is through altered PSD protein
composition and/or interactions72, 75, 78, 88. Thus, based on this evidence, one might
predict that synaptic protein levels would be decreased in the DLPFC of SCZ subjects,
while the protein composition, interactions and/or posttranslational modifications of PSD
proteins would be altered.
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Several research groups, including ours, have investigated the transcription and/or
translation of synaptic genes in the prefrontal cortex using a variety of techniques,
including real time PCR, in situ and Western blot, and micro array. Despite this intense
scrutiny, no consensus has emerged as to the existence or direction of changes in synaptic
protein expressions levels between disease and control tissues (Note, the term expression
is used here, and throughout the text, interchangeably with level and amount and is not
meant to imply that transcription is the sole determiner of mRNA or protein amounts in a
cell). Presynaptic mRNAs were once widely believed to be decreased in the DLPFC of
SCZ subjects95, although a recent review of studies from the last decade shows that
altered expression of presynaptic mRNAs and proteins has not been consistently
observed 96. As for PSD protein and mRNA expression, Table 1-1 reviews the findings of
some of the most recent studies investigating PSD95, NR1, NR2A and NR2B mRNA and
protein levels in the PFC of SCZ patients97-105. This table highlights the lack of
consistency in mRNA findings, as measured by in-situ hybridization and real-time PCR
(qPCR), with most studies
finding either a decrease or
no change in transcriptions.
Western blot (WB)
investigations report more
consistent results, with all
but one study finding no
difference in protein levels
for PSD95 and NR
subunits. Decreased spine
Table 1-1. Translation and transcription of PSD95 and
NMDA receptor subunits have been repeatedly measured in
the PFC of schizophrenia by several methods. This table
summarizes some of the more prominent studies from the last
15 years. Technique: Tech.: Technique used, WB: Western
Blot, IS: in situ hybridization, RT-PCR: Real Time PCR.
Area: the brain area used as reported in the manuscript: FC:
Frontal cortex, PFC: Prefrontal cortex, DL-PFC:
Dorsolateral prefrontal cortex, BA 9: Brodmann Area 9. :
No change Ð: Increase Ï: Decrease. 97-105
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density however, suggests
that total amounts of both
pre- and postsynapticproteins should be
decreased in the DLPFC of
SCZ subjects.

There are two main reasons that likely contribute to these conflicting and
inconsistent results: 1) mRNA and protein levels could be differentially regulated.
The largest discrepancy in the literature is the difference between mRNA and proteins
levels. Differences in the regulation of transcription and translation as well as degradation
of mRNA and proteins are prime candidates to explain these differences. Currently,
technologies for quantifying mRNA are superior to those for protein in terms of
multiplexing, accuracy and throughput. However, mRNA amounts may not reflect
protein amounts. 2) Lack of spatial resolution. One advantage histological studies have
over expression technologies such as real-time PCR and Western blot, is the ability to
resolve the unit being quantified, e.g. spines, in space. The ability to differentiate between
cortical layers, neuronal subtypes and synaptic compartments (e.g. pyramidal neuron vs
inter neuron and spine vs axon terminal) was essential to the successful investigation of
total neuron number, pyramidal cell volume, dendritic branching and spine density.
Thus, the signals of differences in mRNA or protein amount between SCZ and control
tissues that are localized to a specific layer, neuronal type or synaptic compartment could
be lost in the noise of a homogenized tissue sample. The introduction of laser-capture and
linear amplification strategies have mitigated this issue somewhat, allowing for
quantification of mRNAs in discreet cortical layers and specific neuronal populations106108

. Laser-capture – mRNA quantification strategies, however, are still unable to asses

protein amount, partitioning or post-translational modifications.
Considering that the observation of decreased dendritic spines was made in
specific cortical layers and on/about a discreet part of the neuron, the synapse, it is not
surprising that investigations with current strategies have observed either no difference
between SCZ or control or small inconsistent findings. Thus, there is a need to overcome
the technical challenges described above, as identifying the molecular correlates of
decreased spine density is likely essential for linking genetic risk to NR hypofunction.
The observation of these correlates requires an approach with advancements over
traditional strategies that allows for multiplex quantification of synaptic proteins, with
high precision and accuracy and spatial resolution for synaptic microdomains, cortical
layers and neuronal subtypes.
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Several groups have turned to some combination of subcellular fractionation,
immunoprecipitation and/or mass spectrometry (MS) based proteomics to qualify and
quantify synaptic microdomain and receptor complex proteomes in animal tissues109-111.
Unfortunately, MS proteomic strategies as currently configured are ill suited for
addressing this specific question in human tissues. In the next section I provide a brief
review of the more popular quantitative MS proteomics strategies and propose a more
targeted approach to overcome some of the technical hurdles described above.
6. Proteomics strategies in neuroscience
Mass spectrometry (MS) based proteomics has been used extensively to catalog
protein expression in neuronal systems109-115, 160, but application to the study of human
disease has been limited116, 117. Technical hurdles have precluded quantitative proteomics
investigations of synaptic microdomains, fine brain areas and discrete cell types in patient
populations as sensitive and high-throughput proteomics methods have lagged behind
technologies for assaying DNA and RNA. The last two decades have witnessed an
explosion of sequencing, expression array and RT-PCR technologies, allowing for the
routine and timely analysis of thousands of transcripts. The addition of linear
amplification strategies118, 119 has allowed these techniques to be applied to selected
neuronal or even sub-neuronal populations. Thus, expression analyses in brain tissues,
discrete layers, and even selected populations are now routinely performed on tens to
hundreds of clinical samples. Proteomics methodologies, while useful for identifying
thousands of proteins in an abundant sample, have been ill suited for the types of analyses
now routinely performed on genetic materials.
6.1

Multi-dimensional protein identification technologies
MS approaches to protein analysis vary, but most workflows share four concepts

features. 1) Enzymatic cleavage of proteins into predictable peptide components. 2)
Separation of proteins and/or peptides to overcome dynamic range differences in
expression. 3) MS assessment of abundant peptide ions followed by isolation,
fragmentation and assessment of peptide fragment ions. 4) Informatics analysis of these
data matching MS spectra to predicted peptide products in a database, culminating with
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the identification of proteins present in the sample. This strategy is often referred to as
Multi-Dimensional Protein Identification Technology (MudPIT)120. Used in this way, MS
based proteomics represents an unparalleled tool for the identification of proteins and
posttranslational modifications (PTMs).
Quantification of these peptide fragments can serve as a quantitative measure of
protein amount. Two popular strategies of quantification in MudPIT are Stable Isotope
Labeling In Cell Culture (SILAC)121122 and isobaric labeling techniques such as isobaric
Tags for Relative and Absolute Quantitation (iTRAQ)109, 123, 124. SILAC has been widely
employed for in vitro studies. The cell type to be studied is grown in media in which the
only source of the amino acids (AA) lysine (K) and leucine (L) are labeled with stable
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C and/or 15N. After several passages, the cells will have fully incorporated the labeled

AA and the resulting “heavy” proteome serves as an internal standard122.
In iTRAQ the digested peptide products are chemically labeled with isobaric
agents. The different isobaric tags will produce fragment ions with different mass to
charge m/z ratios that can be used as a quantitative measure of the tagged peptide.
Proteomes prepared from different samples can be tagged, pooled and analyzed together.
This method has the advantage of allowing for multiplexed samples analysis. Currently
up to eight proteomes can be multiplexed. This strategy also allows for protein
quantification in which a SILAC standard cannot be generated. However, isobaric
labeling strategies are predicated on the assumption that chemical labeling is both
complete and consistent, which may not always be the case. Additionally, concerns have
recently been raised that multiple tagged peptide sequences may contribute to the
quantitative signal assigned to a single peptide identification, confounding fidelity of
protein quantification 125. An additional round of fragmentation may be required to
address this issue, which could decrease the number of proteins quantified and further
complicate an already involved bioinformatics process.
6.2

Limitations of current strategies
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The main drawback to both
these strategies is the heroic
separations efforts necessary
to overcome the large
dynamic range of protein
expression. Abundant
proteins can confound the
observation and
quantification of less
abundant species in several
ways. Ion trap
instrumentation widely used
for these types of
experiments is limited in both
the number of ions it can
hold and sequence (and thus,
quantify) in a given time.
More abundant peptides will
be sequenced first at the
expense of less abundant
species. Thus deep analysis
of a proteome requires
fractionating the sample as
much as possible. In practice

Figure 1-3. Selected reaction monitoring (SRM). A,
depicts triple quadrupole MS selecting for “light” version
of the peptide LIEDNEYTAR. In the first quadrupole
(Q1) the mass-to-charge ratio (m/z) of the peptide (612.3)
is selected for, conveying it the second quadrupole (Q2)
while discarding other ions (filtered out by m/z). In the Q2
the peptide ion collides with an inert gas, often argon, and
fragments into smaller polypeptides, which are conveyed
to the third and final quadrupole (Q3). Here an m/z,
corresponding with a known fragment ion (997.4), is
selected to move onto the detector, while all other m/z’s
are discarded. B. Depicts the same operation performed on
“heavy” (stable isotope labeled) LIEDNEYTAR. C.
Chromatograms resulting from the selected monitoring of
the “light” and “heavy” species of LIEDNEYTAR when
the SRM is coupled with liquid chromatography.
Calculating the area under the curve for each peak, and
utilizing the “heavy” peptide as a standard facilitates
relative or absolute quantification of the selected peptide in
a complex biological matrix.

this results in two dimension of separation. The first dimension is often strong cation
exchange or hydrophilic interaction chromatography to separate peptides or 1D gel
electrophoresis to separate proteins, both resulting in tens of fractions. These fractions are
then separated in a second dimension, often reverse phase chromatography, over
gradients of one to two hours. Thus, in the absence of multiplexing, the time requirement
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for analysis of a single sample can approach twenty-four hours. Additionally, MudPIT
has relatively high protein requirements, which is problematic if the goal is to assay
protein composition of microdomain enrichments, neuronal layers or discreet neuronal
populations. In the limited number of quantitative proteomics studies performed on
human brain tissue to date, the time and protein requirements have often necessitated
subject pooling, severely limiting statistical power and eliminating the ability to observed
protein patterns of individuals. Clearly, if quantitative proteomics is to meet the
challenges described at the end of section 5, a new strategy is required.
6.3

Selected reaction monitoring, a more selective approach
Selected reaction monitoring (SRM) is a MS methodology routinely used for the

quantification for specific ions in a complex sample matrix126-128. As opposed to the
quantitative MudPIT strategies described above, SRM is usually performed on a triple
stage quadrupole (QqQ) MS instrument. When configured for peptide quantification, the
first quadrupole selects for the m/z of the peptide conveying it the second quadrupole
while discarding other m/z’s. In the second quadrupole the peptide ion collides with an
inert gas, often argon, and fragments into smaller polypeptides ions, which are conveyed
to the third and final quadrupole. Here an m/z, corresponding with a known fragment ion,
is selected to move onto a detector, while all other m/z’s are discarded (Figure 1-3).
Coupled with high performance liquid chromatography (HPLC), the filtering for two
m/z’s specific to a target peptide SRMs on QqQ instruments can monitor the intensity of
a that peptide in a highly complex biological matrix. The addition of a stable isotope
labeled internal standard facilities accurate quantification128. State of the art QqQ
instruments can perform this operation up to 200 times in a second while maintaining
sensitivity in the attomole range. Additionally, SRMs can be timed to correspond with
peptide elution in HPLC. Thus with a priori knowledge SRM strategies can facilitate the
quantification of hundreds of target peptides in a complex matrix. The development and
application of this type of approach is described in detail in Chapter 3.
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7. Summary and Research Scope
Multiple lines of evidence implicate decreased spine density, perturbed
neuroplasticity and NR hypofunction in the pathology of SCZ. NRs are localized to
PSDs, where extra- and intra-synaptic factors converge non-linearly to regulate NR
activity and neuroplasticity, while PSDs are located at dendritic spines. Many SCZ risk
genes code for PSD proteins, implicating the PSD as a site of convergence at which
genetic risk factors converge to impair plasticity over development.
Decreased spine density in the DLPFC of SCZ subject suggest that levels of PSD
proteins could be decreased as well, while some combination of altered PSD protein
amount, partitioning, interactions and posttranslational modifications likely underlie NR
hypofunction. These same molecular correlates of decreased spine density and NR
function are believed to fingerprints of genetic risk factors. Thus, the elucidation of these
molecular differences between SCZ and control is currently an important goal of SCZ
research.
Investigation of molecular alterations in postmortem brain tissue of patients has
been hindered by the lack an approach capable of assaying large numbers of proteins,
with high sensitivity, accuracy, precision, throughput and spatial resolution. The goal of
this thesis work is to develop and validate an MS based method to meet some of these
needs and utilize it to investigate PSD protein expression and partitioning in the DLPFC
of SCZ subjects.
The following aims were developed to address these goals and represent the scope of this
thesis research:
Research Aim I
Catalog the proteins present in PSD enrichments prepared from human postmortem brain
tissue to generate the database necessary for development of an MS method.
Research Aim II
Develop and validate an LC-SRM/MS method for the selective quantification of
hundreds of targeted mammalian synaptic proteins, and utilize this method to further
validate biochemical fractionation of human postmortem brain tissue.
Research Aim III
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Characterize protein expression and PSD protein composition in the lateral PFC of SCZ
and matched control subjects.
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CHAPTER TWO
CHARACTERIZATION OF HUMAN POSTSYNAPTIC
DENSITY PROTEOMES

Data from this chapter was published as:
Hahn CG, Banerjee A, Macdonald ML, Cho DS, Kamins J, Nie Z, Borgmann-Winter KE,
Grosser T, Pizarro A, Ciccimaro E, Arnold SE, Wang HY, Blair IA. The post-synaptic
density of human postmortem brain tissues: an experimental study paradigm for
neuropsychiatric illnesses. PLoS One, 2009
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1. Abstract
Recent molecular genetics studies have suggested various trans-synaptic processes for
pathophysiologic mechanisms of neuropsychiatric illnesses. Examination of pre- and
post-synaptic scaffolds in the brains of patients would greatly aid further investigation.
Biochemical fractionation in human postmortem tissue has yet to be tested and current
proteomics methods used to analyze these preparations in animal models are not well
suited for clinical applications. I performed a two-dimensional liquid chromatographytandem mass spectrometry (2D LC-MS/MS) analysis of human PSD fractions, prepared
with a protocol validated by Western blot (WB) and electron microscopy (EM). This
study represents the first analysis of PSD enrichments from human tissue. Over 1800
proteins were observed and were striking similar to data sets generated by similar
analyses of rodent tissues. These results demonstrate that PSD fractions isolated from
human postmortem brain tissues are assayable by MS proteomics, and lay the foundation
for development of a targeted quantitative method.
2. Introduction
Recent studies in neuropsychiatric illnesses have implicated various trans-synaptic
mechanisms72, 74, 75, for which protein compositions in sub-cellular microdomains are
crucial44, 59, 129, 130 [8-12]. The postsytnaptic density (PSD) is a particularly interesting
microdomain since multiple candidate genes for psychoses and mood disorders converge
on their signaling mechanisms72, 74, 7577. Thus, the ability to isolate these domains and
quantify the proteins there in will greatly aid our understanding of neuropsychiatric
illnesses. We, and others, have recently applied similar approaches to human
postmortem brains 131, 132, but the feasibility and validity have not been fully elucidated.
Additionally, while the MS proteomics strategies described in Chapter 1 have been
extensively utilized for microdomains derived from rodent brains109, 133, 134 [14-17], they
are ill suited for clinical studies as throughput is limited. A targeted approach with
greater throughput and sensitivity is required111. The design of this type of method first
requires a qualitative analysis of the target proteome, which has not been performed in
microdomains prepared from human postmortem brain tissue. In this study, the protein
composition of biochemical fractions enriched in the PSD of human postmortem brains is
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evaluated by two-dimensional liquid chromatography-tandem mass spectrometry (2DLCMS/MS).
The PSD is a highly organized biochemical apparatus attached to the postsynaptic
membrane129, which can be visualized as an electron dense thickening under electron
microscopy. The PSD contains glutamatergic receptors, N-methyl-D-aspartic acid
(NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA),
the group I metabotropic glutamate receptors (mGluRs) and numerous signaling
molecules129. As a molecular scaffold, the PSD brings together various sets of signaling
molecules and modulates their interactions and their activities.
The PSD is relatively insoluble in non-ionic detergents and can be purified by
differential centrifugation 135. Various protocols have been used to isolate the PSD from
rodent brains based on a fundamental principle of: a) purification of synaptic membranes,
b) extraction of the membranes with non-ionic detergents and c) separation of the
resultant disk-shaped protein structures. Protocols have often differed in the degree of
detergent extraction, thereby determining the inclusiveness of proteins in the final
fractions. These include Triton X-100 or N-lauryl sarcosinate and the use of harsher
detergents retrieves a more stripped down version of proteins135. Indeed, variations of
these methods allowed separation of fractions containing synaptic vesicles and synaptic
membranes from the PSD136, 137.
Protein composition of protein complexes can be profiled using proteomic
analysis. Several groups have analyzed the rodent PSD using 2D fluorescence difference
gel electrophoresis (2D DIGE) or LC-MS/MS and identified sets of proteins, including
known PSD proteins previously characterized by the immunoblot method111, 115.
However, depending on the methods of fractionation and proteomics analysis, these
studies have reported variable numbers of proteins in PSD enrichments, ranging from a
few hundred to more than a thousand. Posttranslational modifications (PTM) appear to be
maintained through the rigorous biochemical fractionation procedure, and groups have
identified phosphorylation sites on PSD proteins109, 134, 138, 139. Biochemical fractionation
of postmortem brain tissues faces special challenges due to various confounding factors
inherent to these tissues140, 140. They include prolonged agonal state, complicating
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medical conditions, the post-mortem interval (PMI), inconsistent pH, and duration of
storage and temperature of the tissues. These conditions are thought to disrupt the
integrity of proteins, ultrastructures or microdomains141-143. Therefore, few attempts have
been made to isolate the PSD or other sub-cellular fractions from human postmortem
brains [37]. In the present study, we have isolated PSD fractions from human
postmortem brain tissues, verified the enrichment, protein composition, and integrity of
ultrastructures using Western blot, electron microscopy and performed qualitative
proteomic analysis.
3. Materials and Methods
3.1

Human tissues:
Tissue samples were dissected from the prefrontal cortex (Brodmann area 9) of

two healthy control human brain samples in order to provide sufficient confidence in
protein identifications. Consent for tissue collection was granted prospectively by
patients and autopsy consent granted by the next-of-kin at time of death. The
postmortem enrollment was conducted under Conte Core A, IRB number 703835 and
postmortem protocol was conducted under IRB number 188200.
3.2

Biochemical fractionation:
300-350 mg of frozen postmortem brain tissue was dissected and homogenized in

1.5ml of solution A (0.1mM CaCl2, 1mM MgCl2 and 0.32M sucrose) supplemented with
protease and phosphatase inhibitor cocktails (Sigma). This homogenate was adjusted to
1.25M Sucrose and 0.1mM CaCl2 to a total volume of 5ml. 5ml of 1M sucrose was
overlaid on this and ultracentrifuged at 28000 rpm (100,000×g) for 3 hrs in a SW 40 Ti
rotor using a Beckmann L7 Ultracentrifuge. The band at the interface of 1.25 and 1 was
collected with a needle as SPM. The SPM was diluted with 5X 0.1mM CaCl2 and
centrifuged at 12000rpm (15000×g) for 20 minutes.
For PSD preparation, a 500μl aliquot of SPM was diluted with ice cold 0.1mM
CaCl2 to 2.5ml, followed by the addition of 2.5ml of 40 mM Tris-HCl pH 6
supplemented with 2% Triton-X 100 and protease and phosphatase inhibitors, bringing
the final volume to 5ml with 20mM Tris and 1% Triton-X 100. The samples were left in
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cold room rocker for 30 minutes and centrifuged at 18000 rpm (35,000×g) for 20
minutes. The supernatant, designated as the vesicular fraction (SV), was then diluted
with 5X chilled acetone and left in -20°C overnight. The pellet was air dried and
dissolved in 1 ml CaCl2, then 1 ml 40mM Tris pH 8 with 2% Triton-X 100 , was added
for the final concentration of 20mM Tris and 1% Triton-X. The sample was left on a
rocker for 60 minutes and centrifuged at 36000 rpm (140,000×g) for 30 minutes. The
supernatant, designated as the parasynaptic membrane fraction was acetone precipitated
at -20°C overnight. The pelleted PSD was air dried and dissolved in 20mM Tris pH 7.4.
Acetone precipitated SV and PPF fractions were centrifuged at 15000 rpm (24,000×g) for
30 minutes and pellets were dissolved in 500μl of 20mM Tris pH 7.4 with triple
detergent.
3.3

Western Blotting:
The samples were transferred on PVDF membrane (Millipore) and probed with

the following antibodies: mouse monoclonal PSD-95, 1:1000 (Upstate or NeuroMab, UC
Davis, CA), rabbit polyclonal pS295-PSD-95 1:250 (Abcam), mouse monoclonal
synaptophysin 1:5000 (Chemicon), mouse monoclonal β-actin 1:5000 (Sigma), rabbit
polyclonal ErbB4, goat polyclonal NR1, goat polyclonal NR2A (Santa Cruz) , NR2B
1:1000 (a gift from Dr. Barry Wolfe, Georgetown University Medical Center,
Washington, DC 20057, USA), rabbit polyclonal vGlut1 (Synaptic System), mouse
monoclonal Munc18 and RAB3 (BD Biosciences). The blots were developed using
chemiluminescent reagents ECL or ECL-Plus, or a combination of both (GE Healthcare).
400 µgs of SF or 10 µg of PSD from the same subject were immunoprecipitated after 2
hours preclearing with Protein A agarose with 6 µg of goat polyclonal NR1 antibody
(Santa Cruz) in immunoprecipitation buffer (25 mM Tris-HCl, pH 7.4, 200 mM NaCl, 2
mM EDTA, 0.5 mM EGTA supplemented with protease and phosphatase inhibitors from
Sigma) at 4°C overnight. The samples were incubated with 25 µl of Protein A agarose
Plus (Pierce) for 2 hrs at RT. The immunoprecipitated samples were separated on a 7.5%
SDS precast gel (Biorad) and probed with mouse monoclonal PSD-95, 1:1000
(NeuroMab), Goat Polyclonal NR1 and NR2A 1:500 and mouse monoclonal PLCγ1
1:250 (Santa Cruz).
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3.4

Electron Microscopy:
Pellets were fixed in 2.5%

glutaraldehyde/2%
paraformaldehyde, embedded in
epon, and post-stained with urayl
acetate and bismuth subnitrite.
Ultrastructural examination was
performed with a JEOL JEM -1010
electron microscope. Images were
captured with a Hamamatsu CCD
ORCA digital camera, using AMT
Advantage software version
5.4.2.308 (Advanced Microscopy
Techniques).
3.5

Multidimensional

fractionation-tandem mass
spectrometry:
PSD fractions were
prepared and purity confirmed by
western blot analysis of PDZ
domain and synaptophysin (Figure
2-1). Each pellet was washed 3
times with 20mM Tris pH 7.4 at

Figure 2-1. Subcellular fractions were analyzed by
WB. Abbreviations: T: total tissue extracts, C:
cytosolic extracts, S: SPM, synaptosomal membrane,
V: SV, vesicular fraction, P: PPF: presynaptic
fraction, D′: PSD isolated by the method 1, ’: D:PSD
isolated by the method 3. NR: NMDA receptor,
Synph: synaptophysin, vGlut1: vesicular glutamate
reuptake site.

4°C and suspended in 25mM ammonium bicarbonate with 6M guanidine hydrochloride.
Protein concentration was determined by Coomassie Plus reagent (Promega, Madison,
WI) with a BSA standard curve read at 595nm on an EL808 Microplate Absorbance
Reader (BioTek, Winooski, VT. Two enrichments per biological sample were pooled to
give 600 µg PSD protein. 2D LC-MS/MS was performed using a variation of the method
described by Trinidad et al. 109. Cysteine side chains were reduced and alkylated by
incubation with 5mM dithiothreitol (DTT) for 45 min at 60°C and 15mM iodoacetamide
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for 45 min at room temperature in the dark. The mixture was diluted to a final
concentration of 1M guanidine with 25mM ammonium bicarbonate and 75µg modified
trypsin (Promega, Madison, WI). The mixture was adjusted to a pH of 8.0 and incubated
for 12 hrs at 37°C. Digests were desalted with a Peptide Macrotrap Cartridge
(MICHROM Bioresources, Inc, Auburn, CA) and lyophilized to ∼5 µl. Peptides were resuspended in 100µl strong cation exchange (SCX) buffer A (30% acetonitrile, 5mM
KH2PO4, pH 2.7). SCX was performed on the entire sample using an Agilent 1100 series
HPLC with Chem Station for LC (Agilent Technologies, Santa Clara, CA) using a
PolySULFOETHYL column, 2.1mmID x 100mm, 5µ, 300Å (The Nest Group,
Southborough, MA). SCX buffer B consisted of buffer A with 350mM KCL. The
gradient was held at 0% B for 9 min and then went from 0% B to 29% B over 54 min,
29% B to 75% B over 45 min, and 75% B to 100% B over 9 min, with a flow rate of 100
µl/min. Fractions were collected every three minutes. The first 5 fractions were pooled,
giving a total of ~ 50 fractions per sample. Fractions were lyophilized and re-suspended
in reverse phase (RP) buffer A (0.5% acetonitrile 0.1% formic acid in H20). One tenth of
each individual SCX fractions was injected on a 5µl loop from a CTC pal auto-sampler
(Leap technologies, Carrboro, NC) and peptides loaded onto Vydac Everest C18 column,
300Å, 5µm, 100mm, 500µm ID (The Nest Group) at 20 µl/min in 100% RP buffer A
with an Express C100 system (Eksigent Technologies, Dublin, CA). The mobile phase
was diverted to waste for the first 10 min to remove KCl and other salts. The flow rate
was then reduced to 12µl/min and peptides were eluted over a 50 min gradient from 0%
to 40% RP buffer B (5% H20, .1% formic acid in acetonitrile). After elution the column
was washed for 10 min with 100% RP buffer B and equilibrated for 10 min with 100%
RP buffer A. The LTQ mass spectrometer (ThermoFisher Scientific, San Jose, CA) was
operated in the positive ion mode using electrospray ionization with a capillary
temperature of 200°C. Nitrogen was used as a sheath gas at 41 and an auxiliary gas at 12
(arbitrary units). MS spectra were acquired for a mass range of 400 – 1200 m/z over 30
milliseconds. The top 5 most intense ions per spectra were selected and sequenced with a
collision induced dissociation energy (CID) of 35.0 and activation energy of 25 (arbitrary
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units). A dynamic exclusion window was applied to prevent the selected ions from being
sequenced for 200 ms after the initial acquisition.
3.6

Peptide and protein identification and scoring
The data sets were searched against the International Protein Index (IPI) human

protein sequence database (version 3.43, number of protein sequences: 72,346, total
length of database entries: 30,410,250 amino acid residues) for peptide sequences using
SEQUEST 3.1 (ThermoFisher, San Jose, CA). Raw mass spectra were converted to DTA
peak lists using BioWorks Browser 3.2 (ThermoFinnigan) with the following parameter
settings: peptide mass range 300-5000 Da, threshold 10, precursor mass ±1.4 Da, group
scan 1, minimum group count 1, minimum ion count 15. SEQUEST searches specified
that peptides should have a maximum of two internal tryptic cleavage sites and possess
two tryptic termini, with methionine oxidation and cysteine carbamidomethylation as
possible modifications and used a peptide mass tolerance of ±1.4 Da and a fragment ion
tolerance of 0. The search results were converted into pepXML format. Peptide
identification probabilities were calculated by executing PeptideProphet as implemented
in the Trans-Proteomics Pipeline version 2.8 (Institute for Systems Biology, Seattle,
WA)144. SEQUEST results were processed using the "-Ol" tag, which uses ΔCn* values
unchanged.
Results from both biological replicates were combined in a single statistical
analysis of protein expression using the EBP 1.0 as described previously145. Briefly, EBP
estimates both sensitivity and false identification rate and has been validated empirically
for LTQ ion trap data using a reversed/forward sequence database search approach145.
EBP combines the probabilities of correct peptide identification across multiple peptide
searches using a function that returns the maximum probability from consensus
identifications, and penalizes non-consensual identifications. Replicates are integrated by
simultaneously estimating multiple sets of model parameters. Peptides whose sequence
matches multiple proteins are integrated in the analysis using "Occam's Razor", a
principle by which the smallest set of probable proteins that is sufficient to explain the
peptide sequence identifications is chosen. When proteins cannot be reliably
distinguished by unique peptides, they are reported as a protein group. Only proteins with
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expression probabilities corresponding to a false identification rate of less than 0.01 (1%)
were reported (1863 proteins). This was equivalent to expression probabilities of p > 0.90
in this data set. One hundred thirty two additional proteins with p > 0.90 were members
of groups of similar proteins, which could not be distinguished based on the peptide
evidence. A separate analysis utilizing a forward/reversed database yielded near identical
protein identifications at a 1% false positive cut off (data not shown).
MS/MS spectra of at least two peptides each from 63 PSD proteins (Sup. Table 21) were validated by comparison with product ions estimated from ProteinProspector
(v4.27.2, http://169.230.19.26:8080/). Peptides from select proteins (Sup. Table 2-1)
were subjected to targeted MS/MS analysis to further confirm peptide and protein
identifications. These addition spectra were not included in LC-MS/MS data analysis
statistics.
3.7

Comparison of PSD proteins with previous datasets:
Orthologous sequences for proteins identified in rat and mouse PSD enrichments

from Dosemeci et al. and Trinidad et al., respectively, and our human data set were
derived from the Mouse and Rat Genome Database (MGD,
http://www.informatics.jax.org/). In our data set we saw evidence for 5338 unique IPI
protein accessions collected into 2728 protein groups, where each member of a group was
indistinguishable from the other, usually different isoforms of a single protein, based on
observed peptides. IPI identifiers were assigned to these using the cross-reference
information for each entry. These sequences were compared by analyzing the sequence
homology between them using BLAST 41. The search was performed using the
BLOSUM62 matrix, with gap and extension penalties of 11 and 2, respectively and with
a sequence homology cutoff of 90%.
4. Results
4.1

EM and Western Blot analysis of PSD fractions
The integrity of isolated fractions was tested using EM. Figure 2-2A and B show

a thin section electron micrograph of SPM and demonstrate strikingly intact synaptsomes
that contain synaptic vesicles and filamentous connections to other synaptosomes. Figure
2-2C represents soluble fraction of pH 6 TritonX-100 extraction and shows paired pieces
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of electron dense membranes. The more electron dense membrane is thought to be
postsynaptic. Figure 2-2D shows that PSD fraction is largely devoid of the fine
substructures of synaptic junctions.
The relative purity of these fractions was examined by immunoblotting analysis.
Figure 2-1 shows that PSD proteins, NMDAR1, NMDAR2, Homer and PSD-95, were
enriched in the PSD fractions, while these proteins are much less represented in the
vesicular or parasynaptic fractions. In contrast, presynaptic proteins, Rab3, NRG1,
synaptophorin, vGAT, vGlut1, were mostly enriched in fraction vesicular but not in the
PSD fraction.
4.2

Protein identification
Two biological samples

of PSD fractions, enriched by
Method 2, were analyzed by 2D
LC-MS/MS. Peptide
identifications were assigned
by SEQUEST (ThermoFisher)
and peptide and protein
probabilities determined by
Empirical Bayes Protein
Identifier (EBP). At a 1% false
positive threshold 1863
nonredundant proteins or
protein groups were identified.
A separate analysis utilizing a
reverse database yielded near
identical protein identifications
at a 1% false positive cut off
(data not shown).
Inspection of the

Figure 2-2. (A, B) Thin sections of SPM pellets show
surprisingly intact synaptosomes and intact synaptic
vesicles (A, B) as well as filamentous crossbridges (see
arrows in B). (C) Synaptic membrane fractions extracted
by Triton-X 100 at pH 6.0 show paired electron dense
profiles representing synaptic junctions (see arrows in C).
(D) PSD fraction obtained as an insoluble phase after
synaptic membranes were extracted with Triton-X 100 at
pH 8.0. Note that presynaptic specialization is removed
and that the PSD is thinner than shown in A and B.
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identifications revealed proteins with well-theorized functions in the PSD, as identified
by review of recent literature109, 146, such as the Discs Large Homologs (IPI00552511,
IPI00647950 & IPI00790650), Homer (IPI00003566), SHANK (IPI00019794), G
proteins (e.g. IPI00290928), glutamate receptors (e.g. IPI00297933), and various kinases
(e.g. IPI00007128) and phosphatases (e.g. IPI00008380). Peptides from 36 consensus
PSD proteins, as identified in Collins et al. 147, were selected and confirmed by spectra
inspection and/or targeted MS2 analysis of peptide ions. The complete data set can be
viewed at Peptide Atlas, sample IDs 040804_HumanBrain and 052104_HumanBrain.
For a complete list of proteins and protein groups see: Supplemental Table 2-2 (Appendix
2) or http://spreadsheets.google.com/pub?key=pDgU17zRNrsAy-GrFicBkLQ
4.3

Grouping of protein identifications
To gain a broader view of these data, protein identifications were grouped by

cellular compartment, biological process and molecular function using gene ontology
(GO) annotations where available (Supplemental Figure 2-1A, B & C). While many
proteins segregated to biological processes and molecular functions associated with the
PSD, such as localization, stimuli response, molecular transduction, structural, and
regulators of enzymatic activity, a large number of the proteins were found to be involved
in processes not associated with the PSD most notably metabolism and gene expression.
These types of contaminants have routinely been observed in similar analyses PSDs
prepared from rodents. While it is possible that these identifications represent proteins
with hitherto unknown function in the microdomain, they are much more likely
contaminants from the biochemical fractionation, the result of either close association
with the PSD microdomain (presynaptic proteins) or common biopsychical properties
(mitochondrial membranes).
4.4

Comparison to similar analyses of rodent PSDs
We sought to further validate our findings by comparing our data set to those

from previous LC-MS/MS analyses of mammalian PSD enrichments. To that end we
compared our protein identifications to those obtained from mouse brain PSD
enrichments148and an IP of the PSD-95 protein complex from rat brain PSD enrichments
149

. Close to 800 proteins were shared between the Trinidad dataset and our own when
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compared by sequence homology of >90% including PSD proteins and likely
contaminants such as mitochondrial, ribosomal and pre-synaptic (Data not shown).
Additionally, when compared by sequence homology 28 of the 62 proteins listed in
Supplemental Table 2-1 were found in one or both of the rodent sets. To reduce the
impact of sequence variation between species, the proteins reported in Supplemental
Table 2-1 were compared to the rodent data sets by IPI identifier. In this analysis, all but
10 of the 63 theorized proteins we found were present in one or both of the rodent data
sets.
5. Discussion
2D LC-MS/MS was employed to characterize the protein composition of PSD
fractions. PSD enrichments from two biological samples were combined in a statistical
analysis, which integrates data from consensual and non-consensual peptide
identifications in a Bayesian fashion145. Our list of identified proteins appears highly
inclusive, yet provides an extensive coverage of known PSD proteins, as evidenced by
the proteins cataloged in Supplemental Table 2-1. The number of proteins in the PSD is
presently unknown 146. Using immuno-EM, EM tomography, and scanning transmission
EM, Chen et al (2005) and Petersen et al (2003) have estimated that an average PSD with
a 360 nm diameter and a total molecular mass of 1.10±0.36 gigadaltons, could be
composed of 10,000 proteins of 100kD150, 151.
Proteomic analyses are prone to detecting contaminants that are either highly
abundant in target tissues or co-enriched during biochemical fractionation 146. Indeed, this
list high highly comparable to an analysis of mouse PSDs that utilized a similar 2DLCMS/MS strategy in terms of both confirmed PSD proteins and suspected contaminants.
The next step is to determine which of these proteins are specific to the PSD or highly
enriched in this microdomain compared to others and total homogenates.
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CHAPTER THREE
DEVELOPMENT AND VALIDATION OF A MASS
SPECTROMETRY METHOD FOR THE
QUANTIFICATION OF TARGETED PROTEINS IN
SUBCELLULAR FRACTIONS PREPARED FROM
HUMAN POSTMORTEM BRAIN TISSUE

Data from this chapter in currently under review
at Molecular and Cellular Proteomics as:
M.L. MacDonald, E. Ciccimaro, A. Banerjee, S.H. Seeholzer, I.A. Blair and CG. Hahn.
Biochemical Fractionation and Stable Isotope Dilution Liquid Chromatography-Mass
Spectrometry for Targeted and Microdomain-Specific Protein Quantification in Human
Postmortem Brain Tissue
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1. Abstract
Synaptic architecture and its adaptive changes require numerous molecular events
that are both highly ordered and complex. A majority of neuropsychiatric illnesses are
complex trait disorders, in which multiple etiologic factors converge at the synapse via
many signaling pathways. Investigating the protein composition of synaptic
microdomains from human patient brain tissues will yield valuable insights into the
interactions of risk genes in many disorders. These types of studies in postmortem tissues
have been limited by the lack of proper study paradigms. Thus, it is necessary not only to
develop strategies to quantify protein and posttranslational modifications at the synapse,
but also to rigorously validate them for use in postmortem human brain tissues. In this
study we describe the development of a liquid chromatography-selected reaction
monitoring method, utilizing a stable isotope-labeled neuronal proteome standard
prepared from the brain tissue of a stable isotope-labeled mouse, for the multiplexed
quantification of target synaptic proteins in mammalian samples. Additionally, we report
the use of this method to validate a biochemical approach for the preparation of synaptic
microdomain enrichments from human postmortem prefrontal cortex. Our data
demonstrate that a targeted mass spectrometry approach with a true neuronal proteome
standard facilitates accurate and precise quantification of over 100 synaptic proteins in
mammalian samples, with the potential to quantify over 1000 proteins. Utilizing this
method, we found that protein enrichments in subcellular fractions prepared from human
postmortem brain tissue were strikingly similar to those prepared from fresh mouse brain
tissue. These findings demonstrate that biochemical fractionation methods paired with
targeted proteomic strategies can be utilized in human brain tissues, with important
implications for the study of neuropsychiatric disease.
2. Introduction
Synaptic architecture and its adaptive changes require numerous molecular events
that are both highly ordered and complex60, 152. Molecular and cellular research into these
processes has, until recently, been limited to technologies that can examine one molecule
to the next within a cascade. In the last decade, mass spectrometry (MS)-based
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proteomic methodologies, paired with biochemical fractionation techniques, have enabled
us to begin cataloging the proteomes and signaling of mammalian synaptic
microdomains60, 111, 153-155 and microdomain specific protein complexes114, 133, 156. These
studies have revealed that synaptic architecture and plasticity involve numerous
interactions between multiple signaling mechanisms with robust crosstalk and protein
interactions114 133 86 109. These findings also dovetail with decades of genetic studies into
neuropsychiatric disease, which have identified dozens of risk genes spread across
multiple pathways at the synapse157, 158. Historically, signaling cascades and molecular
disease models have been depicted as a string of molecular events that are connected in
tandem. Such views were shaped in part by the methodologies that permitted the
measure of a handful of protein events at a time. MS-based proteomic methodologies can
monitor numerous proteins and posttranslational modifications simultaneously,
permitting us to examine signaling pathways in the context of many other intracellular
molecular events. The next challenges in the field of neuroscience will be to establish
methodologies for quantitative assessment of proteomes in specific microdomains of
neural tissues, to monitor these numerous molecular events simultaneously, and to
understand them within the context of nonlinear intracellular trafficking, protein
interactions and posttranslational modifications.
Postmortem brain studies are a critical component of neuropsychiatric research as
brain tissues of patients may harbor pathophysiologic information of the illnesses. A
majority of neuropsychiatric illnesses are complex trait disorders, in which multiple
etiologic factors converge at the synapse via many signaling pathways157, 158. The
application of advanced molecular and cellular technologies to access synaptic
microdomains, however, has been limited in postmortem brains by confounds such as
therapeutic intervention, agonal state, and postmortem interval. Thus, there is a pressing
need to validate and focus these biochemical fractionation and MS proteomic methods for
use with human postmortem brain tissue. The vast majority of previous neuroproteomic
studies have employed two dimensional separation/tandem MS approaches to perform
qualitative analyses of mammalian synaptic preparations133, 153, 155. Protein quantification
has been accomplished utilizing either synthetic stable isotope-labeled peptide
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standards111 or isobaric peptide labeling methods, such as iTRAQ109, 123. Sample workup
can complicate the application of isobaric tagging in an efficient and reproducible
manner159, while synthetic peptide standards are costly and have difficulty controlling for
confounds in sample preparation, most notably protein digestion160. Stable Isotope
Labeling by Amino acids in Cell culture (SILAC) can produce only a partially labeled
neural proteome161 and we have found that full expression levels and synaptic
architecture of brain tissue are difficult to reproduce in fully labeled cultures. The recent
availability of Stable Isotope Labeling in Mammals (SILAM) mouse tissue allows for the
generation of a stable isotope labeled neuroproteome within the context of native tissues
to serve as an internal standard for the quantification of a vast number of proteins162.
Walther et al. recently utilized SILAM tissue to quantify over 4000 proteins in mouse
hippocampus and cortex163. Considering the high level of homology between
mammalian neuronal transcripts75, we investigated the suitability of this stable isotopelabeled proteome to serve as a protein standard for human tissue as well as additional
model organisms.
In this study we first describe the development and validation of liquid
chromatography-selected reaction monitoring (LC-SRM)/MS-based methodology for
studies of mammalian synapses. Quantification of 189 neuronal proteins was conducted
utilizing a [13C6] lysine-labeled brain proteome internal standard ([13C6] brain ISTD)
prepared from [13C6]lysine SILAM mouse brain tissue. We also report the application of
this method to further validate biochemical fractionation of human postmortem brain
tissue for the study of synaptic biology in human disease. We observed highly
reproducible enrichment of proteins into synaptic microdomains in a function- and
family-specific manner. These protein enrichments were remarkably comparable
between fresh-frozen mouse and human postmortem tissues. Additionally, bioinformatic
analyses indicate that this method has the capability to quantify thousands of additional
neuronal proteins in many model systems. These experiments demonstrate that the
biochemical fractionation coupled with LC-SRM/MS and [13C6] brain ISTDs provides a
powerful tool for investigating the protein composition of synaptic microdomains in
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mammalian tissues, with broad application to neuropathology and neurological studies in
humans and model systems.
3. Materials and Methods
3.1

Brain tissues:
Prefrontal cortex (Figure 3-1B) tissue slices from three cognitively and

neurpathologically normal subjects without were obtained from the University of
Pennsylvania (UPenn) Brain Bank. Consent for tissue collection was granted
prospectively by patients. Autopsy consent was granted by the next-of-kin at time of
death. Postmortem enrollment, brain autopsy, and neuropathological assessment were
conducted under UPenn Conte Core A, IRB numbers 703835 and 188200. After death,
the cases were stored at 2-4°C until transport to UPenn, where all autopsies were
performed. Upon sagittal bisection, a hemispheres from each case was cut into coronal
slabs, which were frozen overnight at -80°C and then sealed in plastic bags for long-term
storage at -80°C. Tissue samples from the other hemisphere were fixed and prepared for
microscopic analysis. The cases were examined by trained neuropathologists for gross
and microscopic abnormalities diagnostic of diverse neurodegenerative dementias. We
selected fresh frozen tissue from the prefrontal cortex because its large volume allowed
repeated sampling without depleting resources available for other studies on precious
normal human brain tissue.

Within this restriction, we selected tissues with a wide

range in age, sex, and postmortem interval (PMI) (Figure 3-1B). Mouse brain tissues
consisted of the forebrain plus midbrain olfactory bulb, were dissected from three male
C57/BL6 mice 8-12 months old.
3.2

Biochemical fractionation:
Synaptic fractions were obtained using a biochemical method we previously

validated for use in human postmortem brain tissue (Figure 3-1)153. 300-350 mg grey
matter was homogenized in 1.5 ml solution A (0.32 M sucrose, 1mM MgCl2 and 0.1mM
CaCl2) with a Teflon pestle. ~100 μl of the homogenate (H) was saved, solubilized with
1% SDS and clarified by centrifugation. The remaining homogenate was centrifuged at
2,500 RPM for 15 min. The pellet was discarded and 100 μl of the supernatant agitated
on a rocker at 4°C with a final concentration of 0.5% digitonin, 0.2% sodium cholate and
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0.5% NP-40for 1 h, centrifuged at 14,000 RPM for 20 min, and the supernatant was
saved as the Synaptosomal fraction (SF). The remainder of the supernatant prepared
from the 2500 RPM spin was adjusted to 1.25 M sucrose with 2M sucrose and 1mM
CaCl2to a final volume of 5 ml. 5 ml of 1 M sucrose was overlaid and the gradient
ultracentrifuged at 28,000 rpm for 3 h in a SW 40 Ti rotor using a Beckmann L7
Ultracentrifuge. The band at the interface was collected, diluted 1:10 in 0.1 mM CaCl2
and centrifuged at 12,000 RPM for 20 min. The supernatant was discarded and the pellet,
the intermediate membrane fraction (IM), was dissolved in 1 ml 20 mM Tris pH 6.0 and
sonicated with three 10-second pulses. 1 ml 20 mM Tris pH 6.0 with 2% Triton X-100
(Sigma) was added to the solution and agitated on a rocker at 4°C for 30 min, followed
by centrifugation at 18,000 RPM for 30 min. The supernatant, the Vesicular fraction (V),
was precipitated in acetone at-20°C overnight. The pellet was air dried, dissolved in 1 ml
20 mMTris pH 8.0, sonicated with three 10-second pulses, mixed with 1 ml of 20 mM
Tris pH 8.0 with 2% Triton X-100, agitated on a rocker at 4°C for 45min and centrifuged
at 36,000 RPM for 1 h. The resulting supernatant, the Parasynaptic membrane fraction
(P), was precipitated in acetone at -20°C overnight. The pellet, the PSD fraction (D), was
air dried, washed three times with 20 mM Tris pH 8.0 and dissolved in 300 μl 20 mM
Tris pH 7.4 with 1% SDS. Following acetone precipitation, the V and P fractions were
centrifuged at 3,000 RPM for 30 min and dissolved in 100 μl 20 mM Tris pH 7.4 with
1% SDS.
To prepare the [13C6] brain ISTD, 400 mg labeled MouseExpress brain tissue
(Cambridge Isotopes, MA) was homogenized in 4 ml buffer A as described above,
centrifuged at 1,000 x g for 10 min to clarify, agitated on a rocker at 4°C for 30 min, and
centrifuged at 10,000 x g for 20 min. The pellet, a crude membrane fraction, was
dissolved in 2 ml 20 mM Tris pH 7.4 with 1% SDS. Total protein in all preparations was
quantified with the micro BSA assay (Pierce) and all solutions were supplemented with
protease and phosphate inhibitor cocktails (Sigma) as well as 1 mM sodium fluoride and
sodium orthovanidate (Sigma).
3.3

Sample preparation for LC-SRM/MS and LC-tandem MS (MS/MS):
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Sample preparation for LC-SRM/MS and LC-tandem MS (MS/MS): Synaptic
preparations were mixed with the [13C6] brain ISTD at a ratio of 2:1(μg/μg) and
processed for MS analysis as described in Cheng et al. 2006. Briefly, preparations were
heated with LDS buffer at 95°C for 20 min, separated on a 1.5 mm 4-12% Bis-Tris Gel
(Invitrogen), cut into three fractions for LC-SRM/MS and five for LC-MS/MS (Figure 31C& D), chopped into ~ 2 mm cubes, washed in 50% acetonitrile (ACN) containing 25
mM NH4HCO3, reduced with 10 mM DTT, alkylated with iodoacetamide (Sigma), and
digested with trypsin (Promega) 1:5 by mass, overnight at 37°C. Peptides were
recovered from gel cubes into 50/50 H2O/ACN with 3% formic acid by vortex-mixing
and sonication for 20 min each. Samples were then desalted with Oasis® HLB cartridges
(Waters), filtered with 0.22 µm Ultra free-MC filter cartridges (Millipore), then dried
almost to completion and suspended in 45μl H2O with .1% formic acid.
3.4

MS methods:
For LC-SRM/MS analyses, all peptide preparations were run on a TSQ Vantage

triple stage quadrupole mass spectrometer (ThermoFisher Scientific) with an Eksigent
2Dnano LC (Eksigent) and a CaptiveSpray source (Michrom). 5 μl (~2.5μg protein)
sample was loaded on to a Magic C18 column (Michrom) at 1 μl/min for 12 min, and
eluted at 750nl/min over a 25 min gradient from 3-35% mobile phase B (ACN containing
.1% formic acid). SRM transitions were timed using 1 – 1.5 min retention windows,
depending on the number of SRMs to be assayed. Transitions were monitored, allowing
for a cycle time of 1 sec, resulting in a dynamic dwell time, never falling below 10 msec.
The MS instrument parameters were as follows: capillary temperature 275 οC, spray
voltage 1100 V, and a collision gas of 1.4 mTorr (argon). The resolving power of the
instrument was set to 0.7 Da (FWHM) for Q1 and Q3. Data were acquired using a chrom
filter peak width of 4.0 sec.
LC-MS/MS analyses were conducted by Dr. Gene Ciccimaro on a Q Exactive
(ThermoFisher Scientific) quadrupole orbi-trap hybrid instrument with an Easy nLC-II
(ThermoFisher Scientific) nano-pump/autosampler. 3μl peptide sample (~ 1 ug) was
loaded and resolved on a 20 cm x 75 µm proteopepII C18 packed tip column over a 90
min gradient at a flow rate of 350 nL/min, 0-35% mobile phase B (ACN, .1 formic acid).
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A data-dependent top 10 method was used to acquire a 70,000 resolution full scan to
trigger 10 17,500 resolution HCD scans. Ions were isolated for MS/MS analysis with a
2.0 Da window on the quadrupole. Average cycle times were 1 sec. Each sample was
analyzed in triplicate.
LC-MS/MS data analysis: Raw files from triplicate injections were searched together
within Proteome Discoverer 1.3 (ThermoFisher Scientific) using SEQUEST and the
human refseq. database (release 47,
ftp://ftp.ncbi.nih.gov/refseq/H_sapiens/mRNA_Prot/). Search parameters allowed trypsin
to cleave after Lysine and Arginine and have 2 missed cleavages. Precursor ion mass
tolerance was set to 15 ppm and fragment ion mass tolerance was 20 mmu. The dynamic
modification of methionine (oxidation = 15.995 Da) and lysine (13C6 = 6.020 Da), in
addition to the static modification of cysteine (carbamidomethylation = 57.021 Da) was
accepted on up to 4 residues per peptide. Within the Proteome Discoverer Software,
SILAC pairs were identified using the “2 plex” workflow node, and all peptides were
rescored using the Percolator164algorithm node. Finally, peptides were filtered at 1%
FDR.
SRM transition design and validation: Method development began with the selection
of ~300 synaptic proteins of interest from published multidimensional MS/MS analyses
of mouse and human brain tissue biochemical fractions109, 153 as well as the LC-MS/MS
analysis described in this study. RAW data from the two analysis of human tissue were
searched in Proteome Discoverer™ 1.1(ThermoFisher Scientific) using SEQUEST.
Proteome Discoverer™files were loaded into ProteinCenter™(ThermoFisher Scientific),
and sorted by function and subcellular location using Gene Ontology (GO) terms.
Targets for inclusion in the LC-SRM/MS assay were selected with a bias towards wellannotated synapse proteins, such as glutamate receptors, kinases, phosphatases, vesicular
fusion, amino acid metabolism, energy metabolism, protein trafficking, ion conductance,
cytoskeleton, and scaffolding. Peptides for proteins of interest were then filtered based
on the following criteria: 1) presence of lysine to incorporate the “heavy” label, 2) nonredundant to a selected protein or protein group (determined by BLAST search) and 3)
100% homology across mouse and human sequences (determined by BLAST search).
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Acceptable peptide sequences, along with MS2 spectra, were imported into Pinpoint™
(Thermo-Scientific). Initially, five mass transitions were selected for each target peptide
and its “heavy” counter-part. Validation experiments were performed in 1:1 mixtures of
human IM fraction and the [13C6] brain ISTD. Pinpoint™ was used to visually and
statistically validate SRM transitions.
3.5

Western blot analysis
To confirm biochemical enrichment, all preparations were assayed by Western

blot for parasynaptic (P), postsynaptic (D) and vesicular (V) proteins prior to MS analysis
(27). Briefly, 10μg of each fraction was separated on 7.5% SDS precast gels (Biorad),
transferred to a PVDF membrane (Millipore), blocked with 5% milk, .05% TBST for 30
min, and probed with the following antibodies: mouse monoclonal PSD-95, 1:1000
(Upstate or NeuroMab, UC Davis, CA), Na/K ATPase channel subunit α 1:1000 (Santa
Cruz) and Gα 1:500 (Cell Signaling). The blots were developed using chemilluminescent
reagents ECL or ECLPlus, or a combination of both (GE Healthcare).
3.6

Modeling of Postmortem Interval in Mice
Modeling of Postmortem Interval in Mice: 10 male 8-12 month old C57/B6 mice

were sacrificed by CO2 and cervical dislocation, per protocol, and placed at 4°C. The
brains were removed from the crania at 0, 4, 8, 12 and 16 h post sacrifice, separated from
the cerebellum and olfactory bulbs, frozen on dry ice, stored at -80°C and subject to
biochemical fractionation. The D fractions were analyzed by LC-SRM/MS as described
above.
3.7

LC-SRM/MS data and statistical analysis
Peak areas and area ratios were calculated within Pinpoint. Raw files generated

by LC-SRM/MS analysis were loaded into Pinpoint files containing target
proteins/peptides/transitions. All individual SRM transitions and integration areas were
manually inspected. Transitions where the signal-to-noise (S/N) ratio of the “labeled”
species below 3 were excluded from analysis. The ratios of the integrated areas for
“light” endogenous peptides and “heavy” [13C6]brain ISTD peptides were calculated to
obtain peptide measures using multiple transitions per peptide. The average of these
peptide ratios determined the relative amount of each protein. Protein enrichment values
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in the SF, V, P and D fractions were calculated by normalizing protein measures in each
fraction to measures in the H fraction. The coefficient of variations (CV), expressed as a
percent, were calculated to assess precision of peptide quantification across injections,
accuracy of protein quantification from multiple peptides, and reproducibility of
fractionation from different animals or subjects.
Unsupervised hierarchical clustering was used to construct self-organized heat
maps of protein and fraction by enrichment values with Cluster 3.0 and Treeview165, 166.
Enrichment values were log2 transformed, median centered by enrichment and fraction,
then normalized by protein and fraction. Un-centered Pearson correlation was used as the
similarity metric and the clustering method was centroid linkage. Pearson correlation
coefficients were calculated in Cluster 3.0. ANOVA, and Student’s t-test were used to
calculate significance for the effects of species and fraction on enrichment CVs, species
and protein group on enrichment values, and PMI and protein group on protein measure.
3.8

Dilution curve preparation
To confirm that “light”/”heavy” peptide SRM measures were within linear range,

a dilution curve was prepared by varying the ratio of a human total homogenate (H)
fraction / [13C6]brain ISTD from 0.05 to 19. Five mixtures were prepared, (μg H/ μg
[13C6]brain ISTD): 1/19, 3/17. 10/10, 17/3 and 19/1. These preparations were analyzed by
LC-SRM/MS in duplicate and the prepared L/H ratio plotted against the observed L/H
ratio for each light-heavy peptide pair.
3.9

Comparison of human and mouse protein sequences
Dr. Steve Seeholzer graciously performed this analysis. Human and mouse

protein sequence databases were assembled from the orthologous protein accessions
listed in the HomoloGene database (http://www.ncbi.nlm.nih.gov/homologene, release
65). The Entrez efetch utility was used to retrieve the mouse and human fasta format
sequences from the Entrez protein database. Proteins were digested in silico with trypsin
while retaining peptides ending with lysine and 6 ≤ length ≤ 25. Human peptides were
additionally filtered to retain only proteotypic peptides. For each human protein, the
number of peptides having an identical amino acid sequence to any mouse peptide was
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tabulated. A separate analysis was limited to the 1400 proteins identified in a proteomic
study of mouse (Bl6) synaptosomes (Seeholzer and Kalb, unpublished).
4. Results
4.1

LC-MS/MS analysis of postmortem human brain intermediate

membrane fraction spiked with [ 1 3 C 6 ] brain ISTD:
The combined analysis of all five gel bands resulted in the identification of 2,556
protein groups by 2 or more unique peptide sequences. In total, 230,841 peptide spectral
matches were attained, allowing for 27,650 unique peptide sequence identifications.
2,802 labeled lysine containing peptides were identified, while 2,211 were
bioinformatically unique to a single protein group and 1,798 were observed as a
“heavy/light” pair. The median heavy/light ratio was 0.27. Supplemental Figure 3-1A
shows the ratio distribution of all observed unique peptide pairs. These unique labeled
peptide pairs corresponded to 619 proteins, 325 of which were represented by 2 or more
unique pairs. Supplemental Figure 3-1B shows the protein distribution by the number of
unique peptide pairs. Dr. Gene Ciccimano performed this analysis.
4.2

Fidelity of Peptide SRMs
To ensure that the desired peptide was assayed, rigorous selection criteria were

employed for the inclusion of peptide LC-SRM/MS transitions. After a peptide met the
three initial criteria described above: non-redundancy, presence of lysine and 100%
sequence homology between mouse and human tissues, multiple validation experiments
were conducted to confirm peptide SRM accuracy. Candidate “light”/“heavy” peptide
SRMs were evaluated for A) retention time, B) similar y-ion ratios (within 25%), C)
presence in the correct gel fraction, and D) a signal to noise greater than 3. Peptide SRM
pairs for which more than one identical peak was observed were omitted. Out of the
approximately 300 initial proteins selected, 2-4 SRMs for 1-4 peptides from 189 proteins
met these criteria (Sup. Table 3-1, Appendix 2). Of these 189, 110 were measured by one
peptide, 53 by two, and 25 by three or more.
4.3

Precision of Protein Quantification
To assess LC-SRM/MS technical precision, four 30 μg aliquots of a human

intermediate membrane fraction were individually mixed with 15 μg [13C6] brain ISTD,
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prepared for LC-SRM/MS analysis and injected in triplicate over several days. A subset
of 118 proteins was monitored in this experiment. First, analytical precision of peptide
quantification over repeated injections was assessed. The median CV for peptide
measures across three repeated injections was 4.3% and CV correlated with the signal
intensity of the light peptide SRM (R2 = .7) (Supplemental Figure 3-2). Variability from
sample preparation was also assessed. The median CV% across 4 repeated preparations
was 3.8%, with the vast majority under 10% (Figures 3-2A&B). Finally, we assessed
precision of protein quantification by calculating variability between the peptides that
were quantified for the same protein. The median CV for proteins quantified with two or
more peptides was 12%, with the majority of CVs being under 20% (Figure 3-2D). This
indicates that LC-SRM/MS with a [13C6]brain ISTD has excellent precision and highly
reproducible sample preparation.
4.4

Quantitative Analysis of Subcellular Fractions
We analyzed the relative protein composition of five neuronal biochemical

fractions: Homogenate (H), Synaptosomal (SF), Vesicular (V), Pre-synaptic density (P)
and Post-Synaptic density (D), prepared from three human postmortem prefrontal cortex
sections and three mouse brains (Figure 3-1). Enrichment was confirmed by Western blot
for protein markers of fractions D, V and P (Figure 3-3). The enrichment of all fractions
except for P from mouse 3 was confirmed. This preparation was analyzed with the other
samples and included in hierarchical clustering, but was dropped from average
enrichment and enrichment variability calculations. The fractions were mixed, 2:1 by
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Figure 3-2. Precision of peptide quantification. To assess variability in sample preparation,
four 30 μg aliquots of a human IM fraction were individually mixed with 15 μg [13C6]brain
ISTD, and analyzed by LC-SRM/MS with triplicate injections. The coefficient of variance,
expressed as a percentage (CV%), was calculated for each peptide measured in the four
fractions. A, depicts the distribution of the peptide CV%s, showing the vast majority under
10%. B, shows light/heavy area ratios for the TYATAEPFIDAK peptide, which is unique to
Synapsin I. Error bars are standard deviations (SD) of the triplicate injections. C,
chromatographic peaks from LC-SRM/MS analysis of TYATAEPFIDAK. CV% of peptide
measures for the same proteins were calculated to assess accuracy of protein measures derived
from multiple peptide SRMs. D, shows the distribution of these CV%s. E, shows the
consistency of peptide measures for the same protein across 6 fractions prepared from human
subject 1.
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mass, with [13C6]brain ISTD, separated into three fractions by SDS-PAGE (Figure 3-1C)
and analyzed by LC-SRM/MS with duplicate injections (Sup. Table 3-1, Appendix 2).
To ensure a continued high level of precision in peptide and protein measurement,
peptide SRMs in this data set were re-evaluated for variability, intensity and signal-tonoise ratio using the criteria described above. Additionally, as post-translational
modifications can confound protein measurements derived from peptide SRMs, peptide
trends across different fractions from the same individual were manually inspected for
consistency, as in Figure 3-2E. Proteins lacking consistent peptide measures were
removed. It is important to note that even minute differences in peptide measurement for
the same protein were consistent across all fractions. For example the
AVFQANQENLPILK peptide, from Na/K ATPase subunit alpha-1, was slightly elevated
in all fractions compared to the other two peptides (Figure 3-2E). The 150 proteins that
met these criteria in both human and mouse preparations were used as the basis for
comparing fractionation between the two species (Sup. Table 3-2, Appendix 2).
4.5

Protein and peptide quantification accuracy
Accuracy of protein measures was assessed by comparison with Western blot for

three synaptic proteins: guanine nucleotide binding protein subunit α, sodium/potassium
ATPase channel subunit α 1 and PSD-95. We observed consistent agreement in relative
protein measures between the two methods (Figure 3-3).
The light/heavy peptide ratios were found to be linear over the range of the
dilution curve for most peptides, with some deviating from linearity at the first and/or last
point. The average R2 for 195 peptides assayed was .96. Figure 3-4 shows representative
dilution curves for CaMKIIα, CDK5, NR1 and PSD95.
4.6

Protein enrichment
Protein enrichment values were calculated by normalizing protein measures in the

SF, V, P and D fractions to protein measures in the H fraction. Averages and CVs of
protein enrichment values and protein measures in H were calculated for each species.
Median CVs for enrichment values were under 30% for all preparations from both
species (Figure 3-4A). In four of the five preparations (H, SF, P and D) the average CV
was significantly lower in mice, but a two-way ANOVA did not reveal a significant
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interaction between species and
fraction p = 0.2. A substantial
number of proteins had CVs
above 30% (Supplemental
Figure 3-3). At first, we
suspected that proteins with
high CVs in a fraction would
have low average enrichment
values, while more abundant
“bona fide” proteins would
have more consistent values.
Regression analysis, however,
found no correlation between
average enrichment value and
CV in any of the fractions (data
not shown), necessitating the
sorting of proteins by both
enrichment value and
variability.
To gain this more
comprehensive view of the
data, unsupervised hierarchical
clustering was used to group
proteins and fraction by protein
enrichment value (Appendix 3,
Sup. Figures 3-6, 3-7 & 3-8).
In both species we observed
segregation of preparations
into discreet groups by fraction
identity (Figure 3-5B & C).

Figure 3-3. Confirmation of protein enrichment in
biochemical fractionation and accuracy of protein
quantification. Prior to LC-SRM/MS analysis, Western
blot was used to confirm success of biochemical
fractionation. Levels of Na/K ATPase channel subunit 1
α, guanine nucleotide binding protein subunit α, and
PSD-95 were used to confirm enrichment of vesicular
(V), parasynaptic (P) and postsynaptic density (D)
fractions, respectively. LC-SRM/MS quantification of
these proteins was then compared to Western blot. A, B
and C, show representative blots and LC-SRM/MS area
ratios from human subject 2. Error bars are standard
deviations of duplicate injections.
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Clustering analysis of human and mouse preparations together revealed that biochemical
fractions within species had the tightest grouping, followed by fraction identity,
regardless of species (Figure 3-5D). Many protein groups clustered by high enrichment
values were both similar across species and in agreement with previously published
analyses of these preparations. Kinases, scaffolding proteins and glutamate receptors
were enriched in postsynaptic density (D) fractions (Figure 3-6A, Supplemental Figure
8A), SNARE complex proteins and vesicular amino acid transporters were enriched in
vesicular (V) fractions (Sup. Figure. 3-8B), and guanine nucleotide binding protein
subunits and voltage-dependent ion channels were enriched in parasynaptic (P) fractions
(Sup. Figure 3-8C). Synaptosomal (SF) fractions were rich in cytosolic enzymes (Sup.
Figure 3-8D). Clustering analysis of human and mouse fractions together also
highlighted two striking differences
between mouse and human preparations.
First, it identified a subset of
“contaminant” proteins that were enriched
in human D fractions, but not in mouse
fractions (Sup. Figure 3-8E). Second, all
septin proteins measured were enriched in
mouse D and P fractions, but not in human
fractions (Sup. Figure 3-8F)

Figure 3-4. Representative dilution curves.
A human total homogenate fraction (H) was
mixed with the [13C6]brain ISTD in the
following ratios (μg): 1/19, 3/17. 10/10, 17/3
and 19/1. These preparations were analyzed
by LC-SRM/MS in duplicate and the
prepared L/H ratio plotted against the
observed average L/H peptide ratio (peptide
measure) for each protein. This figure
show’s representative curves for CaMKIIα,
CDK5, NR1 and PSD95. The 19/1 point is
not shown to highlight the midrange of the
curve, but does not deviate from the slope
reported here.

The enrichment values were
heavily processed prior to hierarchical
clustering. To more closely investigate the
similarities and differences between
human and mouse preparations, we
compared the average enrichment values
for the protein groups identified by the
clustering analysis in V and D. In the V
fraction, enrichment values for vesicular

proteins were more similar to each other in mice, as compared to humans (Figure 3-6B &
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D). In D, enrichment values for kinases, scaffolding proteins and glutamate receptors
were roughly twice as high in mouse (Figure 3-6C & E). A two-way ANOVA confirmed
a significant interaction between species and the protein group for average enrichment
value (p < 0.0001). Enrichment values for the “contaminant” proteins were, on average,
12-fold higher in the human D compared to mouse (p = 0.022), the most extreme of
which was creatine kinase brain isoform with a 72-fold higher enrichment value (Sup.
Figure 3-4A). The septins had, on average, 3-fold higher enrichment values in the mouse
D compared to human D (p = 0.017) (Sup. Figure 3-5). Interestingly, we observed some
reciprocal enrichment between the D and SF fractions for both of these protein families
(Sup. Figures 3-4 and 3-5).
To test if postmortem interval (PMI) contributed to these differences, we analyzed
D fractions prepared from mouse tissues with PMIs ranging from 0 to 16 h. Measures of
“contaminant” proteins in D increased with PMI, while measures for glutamate receptors
and scaffolding proteins decreased (Sup. Figure 3-4C & D). A two-way ANOVA
confirmed a significant interaction between the two protein groups, PSD proteins vs.
contaminants, over PMI (p = .007). The protein measures for the septins in fraction D,
however, increased steadily to a PMI of 12 h, before decreasing after 16 h (Sup. Figure 35C).
5. Discussion
Deregulated synaptic activity is implicated in a host of neurological and psychiatric
diseases, but strategies to address synaptic protein function in human postmortem brain
tissues are limited. Many neuropsychiatric diseases, such as autism, depression and SCZ,
are believed to arise from complex interactions between many synaptic signaling
cascades in specific subcellular microdomains74, 75, 88, 156-158, the remnants of which are
present in the postmortem brain tissues of patients. Therefore, the ability to assess
protein expression and trafficking events in postmortem brain tissue, with high precision
and accuracy, is essential. Various MS-based proteomics strategies have been applied in
rodent and non-human primate tissue, with limited application in postmortem human
tissue109, 111, 116, 155. Here we report, for the first time, the targeted and precise relative
quantification of over 150 synaptic proteins in 5 distinct sub-cellular preparations from
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human postmortem brain tissues. This study demonstrates that the core protein
components of synaptic microdomains are consistently enriched in biochemical fractions
prepared from human tissue. Additionally, we identified proteins whose partitioning
through fractionation is affected by PMI and other postmortem confounds. This
validated fractionation – stable isotope dilution LC-SRM/MS methodology will further
the investigation of synaptic function in a variety of neuropsychiatric diseases.
5.1

LC-SRM/MS

LC-SRM/MS with a 13C6-brain ISTD allowed the simultaneous quantification of over
150 proteins with precision and reproducibility. We observed low variability in peptide
measures over repeated injections (Sup. Figure 3-2) and preparations (Figure 3-2), as well
as a high level of accuracy in protein quantification as assessed by multiple peptide
SRMs (Figure 3-2), Western blot (Figure 3-3) and dilution curve (Figure 3-4). Although
the analytic precision correlated with intensity of the analyte signal (R2 = 0.7), the
median CV for peptide quantification was 4.3% with the majority of peptides < 10%
across three orders of magnitude of signal intensity (Figure 3-2 and Sup. Figure 3-2).
This compares favorably with other multiplexed protein quantification strategies. For
example, antibody based protein arrays, when applied to similar protein preparations
from human postmortem brain tissue, have an average CV of 14% (personal
communication, Dr. Steve Arnold, unpublished data). The [13C6]-brain ISTD was critical
for this high precision over such a large dynamic range. This standard is prepared from
[13C6]lysine SILAM mouse brain tissue, and thus contains labeled peptides at ratios close
to those found in human brain tissues. To better approximate the protein levels we
expected to observe in synaptic fractions, as well as to obtain a “simpler” standard
proteome, we prepared a crude membrane fraction from the labeled mouse brain tissue to
serve as the [13C6]-brain ISTD. This mouse [13C6]-brain ISTD was mixed with the
intermediate membrane fraction from human brain 1:2 (μg/µg), and a bottom up analysis
was conducted on the mixed proteome following a simple gel fractionation, in order to
verify protein levels between the proteomes, as well as to identify additional candidate
peptide pairs for targeted SRM analysis. The results showed peptide pairs with
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Figure 3-5. Overview of protein enrichment. Protein enrichment values were calculated for
each protein in the SF, V, P and D fractions by normalizing measures in each fraction to
protein measures in H. The averages of these values for each fraction were then taken for the
three human and three mouse samples and CV%s calculated. A, reports the median CV% of
protein enrichment values for each fraction. To sort out protein groups and fraction by
enrichment value, unsupervised hierarchical clustering, with Pearson's Correlation as the
similarity metric, was utilized. B, shows clustering analysis of the mouse fractions as a heat
map, C, the human and D, the mouse and human together. E, is the legend for B, C and D,
numbers are arbitrary normalized enrichment values. For full heat maps with protein rows
labeled, see Appendix 3.
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Figure 3-6. Comparison of human and mouse vesicular and postsynaptic density
fractions. A, a zoomed-in image from Figure 4D, depicts enrichment of postsynaptic density
proteins in D fractions prepared from human and mouse tissues. The Pearson's Correlation
Coefficient for this grouping was .72. To more closely contrast human and mouse fractions,
we compared enrichment values for a subset of the proteins grouped in the clustering analysis.
B, shows enrichment of vesicular proteins in the human (V) fraction and D, those proteins in
the mouse V fraction, while C and E show enrichment of kinases, scaffolding proteins and
glutamate receptors in the human and mouse D fractions. Error bars are standard deviations of
three individuals/animals. Note that in C and E, protein enrichment is higher in the fractions
prepared from mouse tissue.
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methodology will further the investigation of synaptic function in a variety of
neuropsychiatric diseases.
5.1

LC-SRM/MS
LC-SRM/MS with a 13C6-brain ISTD allowed the simultaneous quantification of

over 150 proteins with precision and reproducibility. We observed low variability in
peptide measures over repeated injections (Sup. Figure 3-2) and preparations (Figure 32), as well as a high level of accuracy in protein quantification as assessed by multiple
peptide SRMs (Figure 3-2), Western blot (Figure 3-3) and dilution curve (Figure 3-4).
Although the analytic precision correlated with intensity of the analyte signal (R2 = 0.7),
the median CV for peptide quantification was 4.3% with the majority of peptides < 10%
across three orders of magnitude of signal intensity (Figure 3-2 and Sup. Figure 3-2).
This compares favorably with other multiplexed protein quantification strategies. For
example, antibody based protein arrays, when applied to similar protein preparations
from human postmortem brain tissue, have an average CV of 14% (personal
communication, Dr. Steve Arnold, unpublished data). The [13C6]-brain ISTD was critical
for this high precision over such a large dynamic range. This standard is prepared from
[13C6]lysine SILAM mouse brain tissue, and thus contains labeled peptides at ratios close
to those found in human brain tissues. To better approximate the protein levels we
expected to observe in synaptic fractions, as well as to obtain a “simpler” standard
proteome, we prepared a crude membrane fraction from the labeled mouse brain tissue to
serve as the [13C6]-brain ISTD. This mouse [13C6]-brain ISTD was mixed with the
intermediate membrane fraction from human brain 1:2 (μg/µg), and a bottom up analysis
was conducted on the mixed proteome following a simple gel fractionation, in order to
verify protein levels between the proteomes, as well as to identify additional candidate
peptide pairs for targeted SRM analysis. The results showed peptide pairs with
heavy/light ratios ranging from .01 to 100 with a median of 0.27, below the prepared ratio
of 0.5 (Supplemental Figure 3-1A). These discrepancies are unsurprising considering that
different protocols were used to fractionate the tissues; the priority for human tissue
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enrichment was purity, while the labeled mouse tissue was prepared with yield as the
primary objective.
LC-SRM/MS analysis using a [13C6] brain ISTD has several advantages over
multi-dimensional separation tandem MS strategies for protein quantification by several
of the criteria laid out in Chapter 1. First, time requirements for both experiment and data
analysis are greatly reduced. Sample preparation time is reduced, as compared to strong
cation exchange, since gel fractionation yield a minimal number of fractions and allows
for multiplexed sample preparations within a single gel. Indeed, it is likely that for
relatively “simple” proteomes, the first dimension of separation could be omitted.
Gradients for SRM/MS are much shorter than tandem MS approaches in which full
MS/MS data for peptide identification must be collected. Software, such as Pinpoint and
Skyline, has streamlined peptide SRM design, validation and analysis. We validated 189
proteins for LC-SRM/MS quantification with the [13C6] brain ISTD. This number is
dwarfed by multi-dimensional separation tandem MS strategies that utilize labeled ISTDs
or isobaric labeling. However, our bioinformatics analysis indicates that this strategy
could theoretically be applied to 1152/1189 synaptic proteins (Figure 3-7), 1024 of which
have peptides (proteotypic, ending in lysine, 6 ≤ length ≤ 25) that have been identified in
the NIST peptide database. As these libraries grow from incorporation of our own and
others’ discovery data, so will the number of proteins that can be assayed. Additionally,
this methodology will allow researchers to target specific protein families and/or
pathways. Posttranslational modifications are often present in low amounts and can only
be assayed by the observation of a specific peptide, while proteins can be quantified by
numerous peptides. Thus, multi-dimensional separation tandem MS strategies can be ill
suited for the reproducible quantification of protein posttranslational modification
compared to the targeted peptide SRM strategies.
5.2

Comparison of preparations from mouse and human tissues
Chapter 2 reported that postsynaptic densities could be fractionated from the

majority of human postmortem brain tissues153. Here, I utilized the accuracy and
precision of LC-SRM/MS with a [13C6]-brain ISTD to further examine the reproducibility
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of subcellular fractionation in human postmortem brain tissue. I compared the relative
enrichment of over 150 proteins in 4 fractions (SF, V, P & D) prepared from the
prefrontal cortexes of three human subjects and the brain tissues of three mice (Figure 31).
Mouse brains, flash frozen on dry ice immediately after dissection, are mostly free
of the postmortem confounds, as well as individual variability, inherent to human brains.
In these tissues the median variability of protein enrichment was under 30% for all
fractions (Supplemental Figure 3-3). Unsupervised hierarchical clustering of proteins
and fractions by enrichment values revealed tight grouping of fraction types (Figure 35B). The clustering analysis also returned enriched protein groups in line with current
views of synaptic architecture (see Results). Despite the fact that the P fraction from
mouse #3 was identified as an outlier, it still clustered with the other two P fractions
(Sup. Figure 3-6A), demonstrating the power gained from comparing multiple protein
measures.
Human and mouse preparations were compared by enrichment value variability,
hierarchical clustering and relative enrichment levels. Variance in protein expression and
enrichment values tended to be smaller in preparations from mouse tissue (Figure 3-5A,
Sup. Figure 3-3). Considering the individual variability in the humans from which tissue
was derived, most notably age (70, 72 & 98), sex (2F, 1M) and PMI (4, 10 and 15 hours),
protein enrichment in human fractions should be considered rather consistent. Hierarchal
clustering also revealed a striking similarity in enrichment patterns between the same
fractions prepared from different species, while highlighting some key differences
(Figure 3-5D). The enrichments that drove this clustering were composed of welldocumented synaptic molecules (Sup. Figure 3-8). Subcellular fractions prepared from
human tissue are consistently enriched for key synaptic proteins in a manner similar to
mouse tissue, suggesting that the core protein complexes that make up these
microdomains are relatively intact in human postmortem brain despite biochemical
procedures for fractionation. Indeed, our group has previously shown that protein-protein
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interactions at PSD95, a central protein in postsynaptic protein complexes, are preserved
in human brain tissue and survive biochemical fractionation153.
I observed distinct differences between flash frozen mouse and postmortem
human brain tissues. First, although PSD proteins were enriched in D fractions from both
species, the enrichment values were 2x higher in fractions prepared from mice (Figure 36). I also identified a subset of “contaminant” proteins enriched in D fractions prepared
from humans, but not from mice (Sup. Figures 3-4 and 3-8). Interestingly, some of these
proteins were enriched in SF fractions from mice, but none were enriched in human SF
(Sup. Figures 3-4B and 3-8). These proteins are diverse in both function and cellular
localization, suggesting tissue degradation over PMI could cause co-enrichment in the D
fraction, diluting the relative amount of postsynaptic density proteins. Experiments with
D fractions prepared from mouse brain tissues with simulated PMIs support this
assertion. I observed increased amounts of these “contaminant” proteins with decreased
amounts of postsynaptic density proteins as PMI increased (Supplemental Figure 3-4C &
D). Finally, septin proteins were enriched in the D and P fractions from mice, but not
from humans (Supplemental Figures 3-5 and 3-8). Septins are conserved eukaryotic
proteins that form cytoskeleton components that provide membrane rigidity and create
barriers between subcellular domains in many cell types, including neurons167.
Additionally, more specialized roles for individual septin family members have been
identified on both sides of the synapse. For example, Septin 5 has been shown to inhibit
vesicle exocytosis by interacting directly with the SNARE complex168, 169, while Septin
11 plays a functional role in dendritic arborization of GABAergic synapses170. PMI could
not explain the differences in enrichment as septin proteins increased with PMI, in
contrast to the observations in human tissue (Supplemental Figure 3-5C). While
individual septins have known roles at the synapse, the septin cytoskeletons have not
been observed to associate tightly with postsynaptic protein complexes114, 133, 156. In
addition to PMI, another difference between mouse and human tissue is the ratio of white
to grey matter. Human cortex samples are cut to maximize the amount of grey matter in
the tissue sample, while it is not possible to separate the two in mouse brain. I suspect
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this composition of human tissue yields a more pure D fraction in terms of septin
contamination. Further experiments, ideally in grey matter dissected from fresh-frozen
non-human primate tissue, are required to confirm this hypothesis.
Neuropsychiatric illnesses are associated with alterations in synaptic biology,
which involve a multitude of proteins and signaling mechanisms in a microdomainspecific manner. The ability to assay the proteomes of synaptic microdomains, in which
disease factors may converge, is essential to advancing our understanding of these
illnesses. Here, I have validated a fractionation – stable isotope dilution LC-MS
methodology for the precise and targeted quantitation of over 150 synaptic proteins in
subcellular fractions prepared from human postmortem brain tissue. Additionally, we
have demonstrated that this method has the potential to be expanded to >1000 synaptic
proteins. Thus, this study represents the essential first step in bringing targeted proteomic
strategies to bear on the study of neuropsychiatric disease in human brain tissue.
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Figure 3-7. Comparison of human and mouse protein sequences. Protein sequences were
retrieved for human and mouse homologenes from the total proteome and a representative
synaptic proteome. Lysine-containing peptides, between 6 and 25 amino acids in length, were
compared between the two species. This analysis shows that the [13C6]brain ISTD can
theoretically be used to quantify 80% of the human synaptic proteins identified by more than
two peptides. Additionally, the vast majority of these synaptic proteins have peptides in the
NIST Libraries of Peptide Tandem Mass Spectra.
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CHAPTER FOUR
ALTERED PARTITIONING OF POSTSYNAPTIC
DENSITY COMPLEXES IN SCHIZOPHRENIA
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1. Abstract
Several lines of evidence point to the PSD as point of convergence for SCZ
genetic risk factors. PSD signaling is crucial for regulating NMDA rector function, which
is perturbed in SCZ and believed to underlie aberrant plasticity. Additionally, decreased
dendritic spine density has been consistently observed in layers 2 and 3 of the DLPFC in
SCZ patients. Decreased PSD protein expression seems a likely correlate for decreased
spine density, while alter PSD complex protein composition could contribute to NMDA
receptor hypofunction in the DLPFC of SCZ. Interesting, investigations by traditional
methods, qPCR, Western blot and in-situ hybridization, have not consistently observed
decreased PSD protein expression and few studies have investigated the protein
composition of synaptic microdomains in postmortem tissues.
To investigate PSD protein expression and partitioning, the biochemical
fractionation - [13C6]-brain ISTD - LC-SRM/MS method, developed and validated in
Chapter 3, was utilized. 185 proteins were quantified in whole tissue homogenates
prepared from 15 pairs of SCZ subjects and matched controls. 107 proteins were
quantified in PSD enrichments from 9 pairs. Protein expression was largely unaltered
between SCZ and control tissues, while enrichment of PSD proteins was elevated in
preparations from SCZ subjects. Despite this enrichment, the relative amounts of
postsynaptic proteins, normalized to PSD95, was unaltered between the two groups.
These changes could not be attributed to neuroleptics effects, assayed in the PFC tissue of
rhesus monkeys and did not correlate with PMI or subject age. These data suggest that
partitioning, not expression, of PSD complex proteins is the major molecular correlate of
decreased spine density in the LPFC of SCZ.
2. Introduction
Several lines of evidence point to the PSD as a microdomain that will be critical
for the pathophysiology of SCZ: 1) NR hypofunction is widely believed to be a key
component for the pathophysiology of SCZ, hypothesized to be present both throughout
development and in the tissue of elderly patients6, 72, 78, 88. Given that NR complexes are
highly concentrated in the PSD129, 146 and NR activity is critically modulated by PSD
protein composition44, 59, it is highly likely that such functional dysregulation of NRs is
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associated with altered PSD protein compositions and/or interactions. 2) Several SCZ
risk genes, e.g. ErbB4, NRG1, RGS4 and DISC1 directly impact NR signaling at the
PSD72, 74, 77, 88, implicating the PSD as a point of convergence for genetic factors. 3) NR
and PSD complexes are localized to the spines of excitatory synapses. Decreased spine
density has been observed in layers 2 and 3 of the DLPFC without neuronal loss35, 36, 43.
Decreased spine density is likely the result of perturbed neuroplasticity caused by NR
hypofunction94, 171. Thus, dysregulated PSD protein expression and partitioning could be
both cause and consequence of SCZ disease processes. NR hypofunction and the genetics
of disease risk implicate altered PSD protein dynamics, as a cause of dysfunctional
neuroplasticity, while decreased spine density, believed to be the consequence of
dysfunctional neuroplasticity, suggests that PSD protein expression should be decreased
in the DLPFC.
A myriad of strategies have been employed to investigate postsynaptic protein
and transcript levels in the PFC tissues of SCZ subjects in an effort to observe the
predicted molecular dysregulations. However, the results of these studies have been
contradictory (See Table 1-1 for a review of recent findings). While many groups
observe no difference in protein expression between control and disease tissues, other
groups report small differences in one or two mRNA transcripts97-105, but often with low
statistical significance, and without controlling for multiple hypothesis testing. Presently,
there are no consistently observed changes in mRNA or protein expression of PSD
proteins in SCZ.
This lack of consistent observations is perhaps not surprising considering the
complexity of predicted synaptic protein expression and partitioning changes, as well as
the technical hurdles protein and mRNA strategies must overcome to measure them.
Histological studies have the advantage of being able to visualize the object of study (the
spine) allowing for unit quantification and a spatial resolution not achievable in other
molecular assays such as Western blot, real-time PCR and microarray. As for mRNA
quantification, great progress has been made in resolving cortical layers and neuronal
sub-populations106-108. However, while the results of these studies are extremely
informative, they may not be reflective of protein levels in whole cells or spines of
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human postmortem tissue. Likewise immunohistochemistry has special resolution for
protein amounts, but is limited in the number of proteins that can be assayed.
Inconsistencies between mRNA and protein findings in the DLPFC of SCZ
patients could be explained by the following: 1) Current approaches lack the sensitivity,
spatial resolution and, in the case of protein assays, multiplexed capability to observe the
altered protein expression expected to parallel decreased spine density and NR function.
2) The predicted molecular correlates of decreased spine density and NR activity are not
manifested in mRNA and/or protein expression levels, but in altered partitioning,
interactions and posttranslational modifications. 3) Both 1 and 2. That is, protein
expression is unaltered and current approaches lack the precision and resolution to
confirm the null hypothesis with high confidence.
Clearly, approaches with enhanced
sensitivity, spatial resolution and multiplexed
capability, among other methodological
improvements are required to overcome these
technical issues and elucidate the molecular
correlates of decreased dendritic spine and NR
Figure 4-1. Subject age and
postmortem interval. A, shows
subject postmortem interval (PMI)
in hours (h). B, shows subject age in
years (y).

hypofunction. This study represents an attempt to
address some of these technical issues and
perform a more thorough search for molecular
perturbations in the PFC of SCZ. Here,

biochemical fractionation and [13C6]-brain ISTD-LC-SRM/MS were utilized for the
multiplexed quantification of over 200 synaptic proteins in whole tissue homogenates and
over 100 proteins in biochemical PSD enrichments. This approach allowed for the
precise, accurate and multiplexed quantification of synaptic protein expression and
partitioning to the PSD. While this method has spatial resolution for a synaptic
microdomain, the PSD, it cannot resolve between cortical layers or neuronal subtypes.
Thus the experiments described below represent a first step in deciphering the molecular
complexity of the synapse in SCZ.
3. Materials and Methods
65

3.1

Human lateral frontal cortex tissue
Psychiatric subjects met Diagnostic and Statistical Manual of Mental Disorders

Fourth Edition (DSM-IV) diagnostic criteria for SCZ. Diagnosis was determined by
consensus of at least two board-certified research psychiatrists after comprehensive
review of medical records, direct clinical assessments and interviews with caregivers.
Autopsy consent was obtained from the next of kin or a legal guardian in all cases, based
on a protocol approved by the Institutional Review Board at the University of
Pennsylvania. Control and psychiatric subjects were matched for sex, age, smoking
history and postmortem interval (Sup. Table 4-1 and Figure 4-1).
3.2

Rhesus monkey PFC tissue
Dr. Scott Hemby (Wake Forrest University) generously supplied DLPFC tissue

from rhesus monkeys treated with treated with different neuroleptics for six months:
clozapine (5.2 mg/kg daily dose), low does haloperidol (0.14 mg/kg daily dose), high
dose haloperidol (2.0 mg/kg twice daily) and vehicle. Each group consisted of five males
and five females with the exception of the high haloperidol group, which had four of
each. These animals are extensively described elsewhere 172. Only tissue from the male
animals was utilized for the experiments described here, while the females will be
analyzed at a later date.
3.3

Biochemical fractionation
Whole tissue homogenates and PSD enrichments from the lateral PFC (LPFC) of

30 subjects were prepared in three batches (Sup. Table 4-1). Batch 1 was prepared using
a variation of the protocol described in Chapter 3, section 3.2, that omitted the 2500 RPM
spin after the homogenization step. Batch 2 was prepared using the protocol described in
Chapter 3, section 3.2. Due tissue amount limitations, the remaining human tissue and all
rhesus monkey tissues were processed using an abridged protocol:
50 mg grey matter was homogenized in .5 ml solution A (0.32 M sucrose, 1mM
MgCl2 and 0.1mM CaCl2) with a Teflon pestle. ~ 45 μl of the homogenate (H) was
saved, solubilized with 1% SDS and clarified by centrifugation. The remaining
homogenate was centrifuged at 1,000 x g for 10 min to remove nuclei and incompletely
homogenize material. The pellet was discarded and the supernatant (S1) centrifuged at
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10,000 x g for 15 min. The Pellet (P2) was suspended in 120 μl solution A, to which 960
μl .5% Triton X-100 solution (10 mM Tris pH 7.4, 1 mM EDTA, 1mM EGTA) was
added. This mixture was agitated at 4°C for 20 min and then centrifuged at 36,000 RPM
for 20 min. The supernatant (S3) was saved and the pellet (P3) suspended in .5 ml 1 %
Triton X-100 buffer (10 mM Tris pH 7.4, 1 mM EDTA, 1mM EGTA) by pipetting and
probe sonication (three times for 5 seconds on low setting). The mixture was then
agitated at 4°C for 30 min and centrifuged at 36,000 RPM for 30 min. The supernatant
(S4) was saved and the pellet (P4), enriched for the PSD, was dissolved in 200 μl 20 mM
Tris pH 7.4 with 1% SDS. All solutions were supplemented with 1 x protease and
phosphate inhibitor cocktails (Sigma) as well as 1 mM sodium fluoride and sodium
orthovanidate (Sigma). See Supplemental Figure 4-1 for a comparison of representative
PSD and presynaptic protein enrichments from these preparations and those from Chapter
3.
Total protein amounts in all preparations were quantified with the micro BCA
assay in duplicate (Pierce). Success of PSD enrichment was assessed post hoc by LCSRM/MS.
3.3

Sample preparation and LC-SRM/MS:
10 μg PSD enrichments and 20 μg whole tissue homogenate preparations were

mixed with the [13C6] brain ISTD at a ratio of 1:1 (μg/μg) and processed for LC-SRM/MS
analysis as described in Chapter 3, section 3.3, but with one difference. After separation
on a 1.5 mm 4-12% Bis-Tris Gel (Invitrogen), the lane was divided into two fractions at
the 64 kDa marker.
LC-SRM/MS was conducted as described in Chapter 3, section 3.4, with an
expanded set of transitions. Subsequent to the experiments described in Chapter 3,
additional data sets became available and additional proteins of interest were identified
by parallel projects in the Hahn Lab. As of writing, peptide-SRMs for over 200 proteins
have been validated. The development of these additional SRMs drew upon the NIST
and PeptideAtlas databases (Ref), along with a recent 2DLC-MS/MS analysis of mouse
synaptic membrane enrichments performed in Dr. Steve Seeholzers laboratory (Seeholzer
and Kalb unpublished). Human PSD enrichments and homogenates were first assayed for
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a subset of these proteins. This subset included 127 synaptic proteins (Sup. Table 4-3,
Appendix 2) that were either found to be enriched in the PSD (see Chapter 3) or are
known to have postsynaptic roles. For example, a majority of G protein subunits was
neither enriched nor un-enriched in PSD fractions, but are known to be active in
postsynaptic processes (Ref). A handful of presynaptic molecules were also included to
assess purity of PSD enrichments. The homogenate peptide preparations were also
assayed in a separate LC-SRM/MS run for an additional set of 96 non-PSD neuronal
proteins (Sup. Table 4-4, Appendix 2).
3.5

Data processing, informatics and statistics
LC-SRM/MS data was processed as described in Chapter 3, section 3.7, as was

calculation of protein amount and protein enrichment values.
Success of biochemical fractionation was assessed by investigation of enrichment
values for the PSD proteins NR1, PSD95 and CaMKIIα, as well as the SNARE complex
proteins synapsin 2, syntaxin 1B, syntaxin binding protein and synaptobrevin (VAMP).
Subjects for which the two of three PSD protein enrichment values were below 2 and/or
two of the four SNARE complex enrichment values were at or above 1 were dropped
from analysis (calculations not shown).
Three types of data sets were generated from LC-SRM/MS analyses of human and
rhesus monkey PFC preparations: 1) Protein measures in total homogenate preparations,
2) Protein measures in PSD fractions, and 3) Protein enrichment values. Total
homogenate protein measures were normalized to beta tubulin. The rationale for this
choice and the associated caveats are considered in section 5.2 of the discussion. PSD
protein measures were normalized over PSD95 to assess the relative ratios of core PSD
proteins. As in Chapter 3, section 3.7, protein enrichment values were the [PSD protein
measures] / [total homogenate protein measures] without the introduction of an additional
normalization factor.
Outlier subjects or animals were identified by manual inspection for the number of
individual protein or enrichment value outliers and principle component analysis of the
entire dataset, run as a plug-in in Excel. Normalized protein or enrichment value outliers
were defined as > [(Group Mean) + (2 * standard deviation)]. Principle component
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outliers were defined as a subject or animal having two (or more) vector values greater
than two standard deviations away from the vector mean. In the event that a subject or
animal was identified as an outlier by either of these methods, it was only dropped from
analysis provided that its absence did not affect the assignment of significance in all data
analyses (calculations not shown).
The enrichment and expression datasets were processed in a similar fashion: To
begin, the average of protein measures (or protein enrichment values) for each group
(SCZ and CTL) were calculated in Excel, and the distribution of these averages plotted in
GraphPad Prism 5. The ratio of the SCZ average over the control average (SCZ/CTL)
was calculated for each protein, and the distribution of these ratios plotted. The
distribution shape range, mean and median was considered in evaluation of the dataset
and evaluation of normalizing factors. As a preliminary evaluation, two-tailed Students ttest was used to assign P-values to individual proteins for between-group differences
(SCZ vs CTL). Proteins were then ranked by P-value. Proteins with a P-value < .2 were
identified and divided into two groups based by SCZ/CTL ratio: > 1 and < 1. The ranked
protein lists were then submitted, as a list of official gene symbols, to the DAVID
Functional Annotation Tool, and searched for Kegg pathway and gene ontology (GO)
term enrichment. The full list of quantified proteins, submitted as non-redundant
International Protein Index (IPI) identification numbers, served as the background. The
results of this analysis were used to inform the grouping of proteins by direction of
regulation and functional annotation for further analysis. Two-way ANOVA in GraphPad
Prism 5 was used to assign significance of diagnosis (human) or drug (rhesus monkey)
effect on protein measures or enrichment values for identified protein groups.
Considering the relatively loose criteria used to group the proteins and the propensity for
Type I errors in postmortem experiments, a Bonferroni correction was employed in
assigning diagnosis or drug effect significance to grouped protein values. 17 two-way
ANOVAs were run on data from experiments in humans and 17 on data from
experiments in rhesus monkeys, so P-values for assigning significance were set at .0029
(.05/17). P-values determined by T-test for individual protein regulation are reported, but
are not discussed in terms of significance.
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Correlations between subject PMI, age and significantly regulated protein values
were assessed in GraphPad Prism 5. Only the subset of data generated from rhesus
monkey tissue experiments, required to control for neuroleptic drug effects, are reported
here.
Unsupervised hierarchical clustering was performed on a manually selected
subset of non-normalized protein values from human total homogenates, human PSD
enrichments and rhesus monkey PSD enrichments as described in Chapter 3, section 3.7.
4. Results
4.1

Protein levels in whole tissue homogenates
223 proteins were quantified in whole tissue homogenates derived from the LPFC

of 15 SCZ subjects and matched controls. Of these, 185 met the criteria described in
Chapter 3 for inclusion in analysis (Sup. Table 4-5, Appendix 2). Sample #2 (batch 1)
showed inconstancies in HPLC; irregular peptide retention times were observed despite
retiming of the method and multiple LC-SRM/MS runs, requiring the exclusion of
sample #2 from analysis.
Initial analysis began with plotting distributions of average beta tubulinnormalized protein values for each group (SCZ and CTL). Distribution of average
normalized protein values was highly similar between SCZ and control (Sup. Figure 4-2
A&D). Next the ratio of these averages (SCZ/CTL) was taken and the distribution of
these values plotted. The ratios (SCZ/CTL) of average normalized expression values fell
over a normal distribution, ranging from .5 to 1.3 with a median and mean of 1.03 (Figure
4-2A). Of these, twelve were up-regulated in SCZ with a P < .2 (Figure 4-2D). Proteins
with the GO terms macromolecule catabolic process (GO:0009057 P = .004) and protein
amino acid autophosphorylation (GO:0046777, P = .0015), were significantly enriched
against a background of 185 IPI entries. Based on this analysis and a manual inspection
of these data the regulation of all assayed members of the CaMKII family (α, β, δ and γ)
were assessed as a group by two-way ANOVA as were ubiquitin enzymes and
proteasome subunits. CaMKIIs were significantly increased as a group (P = .0002,
Figure 4-2B), as were the proteolysis pathway enzymes proteasome subunit alpha-1
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Figure 4-2. Differentially expressed proteins in the schizophrenic LPFC. Quantitative
measures of 222 proteins, normalized to beta tubulin, were assessed in whole tissue
homogenates prepared from the LPFC of 15 schizophrenic subjects and matched controls and
rhesus monkeys treated with neuroleptics. The average protein measure was taken for each
group and the schizophrenia average divided by the control average (SCZ/CTL) to obtain a
ratio of dysregulation for each protein. A, shows the distribution of these dysregulation ratios.
The tight normal distribution about the mean/median (1.03) is reflective of the low number of
different protein levels between the two groups. D, lists the proteins whose between group
difference has a P-value < .2. P = P-value, two-tails T-test, SCZ/CTL = average
schizophrenia protein value / average control protein value, OGS = Official Gene Symbol. B
and C, show average normalized values for CaMKII (B) and proteolytic (C) proteins in
human samples, while E and F, show the same values in tissues from rhesus monkeys. CTL =
control subjects, SCZ = schizophrenia, Veh = vehicle, Cloz = , L Hal = low dose haloperidol
and H Hal = high dose haloperidol. Error bars are standard error of the mean.

(PSMA1), E3 ubiquitin-protein ligase (UBR4), ubiquitin isopeptidase T (USP5) and
ubiquitin carboxyl-terminal esterase L1 (UCH-L1) (P = .0012, Figure 4-2C).
To control for antipsychotic drug effects, the expression of these proteins was
assessed in total homogenate fractions from rhesus monkeys treated with clozapine, low
haloperidol, high haloperidol or vehicle for six months. While CaMKIIδ was significantly
up-regulated by both doses of haloperidol, none of the antipsychotics induced the broad
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increase of CaMKII proteins observed in SCZ tissue (Figure 4-2E). Antipsychotic drug
treatment had a significant effect on proteasome pathway protein levels (P = .0002). Both
clozapine and high haloperidol induced a small increase in PSMA1 and USP5 levels.
High haloperidol induced a greater up-regulation of USP5, as compared to other
regulations observed in this group. Neither PMI nor age correlated with amounts of these
proteins in human tissue (Sup. Figure 4-5).
4.2

PSD protein enrichment
Enrichments from 9 control and 8 SCZ subjects, representing 8 pairs and one

orphan control subject from batches 2 and 3, and all enrichments from rhesus monkey
tissue met the criteria for inclusion described above. 107 synaptic proteins were
quantified in these PSD preparations (Sup. Table 4-3, Appendix 2). Enrichment values
for 104 of the synaptic proteins were calculated (Sup. Table 4-6, Appendix 2). In light of
potential confounds due to the different protocols used to enrich PSD fractions in batches
2 and 3, data analysis was performed on the six pairs from batch 3 as a stand-alone data
set (referred to henceforth as “6 pairs”) and on batches 2 and 3 together (referred to
henceforth as “9 pairs”). Batch 2 consisted of only three pairs, lacking the statistical
power to be considered alone.
Principle component analysis did not identify any subject or animal as an outlier
(data not shown), but enrichment values for the majority of PSD proteins in sample #22
were outliers when considered in the context of 9 pairs, but not of 6 pairs. The removal
of this sample (#22) from the 9 pairs dataset did not alter the statistical outcome of any of
the analyses detailed below. For these reasons, sample #22 was dropped from the 9 pairs
analysis.
The ratio (SCZ/CTL) of average enrichment values for 6 pairs ranged from .23 to
1.64 in a graphical shape suggesting an asymmetrical bimodal distribution (Sup Figure 43A). The median and mean were 1.05. Of the 6 pairs enrichment values, 22 were
elevated and 10 were decreased in SCZ as compared to controls with a P < .2 (Sup.
Tables 4-2A & B). The ratio (SCZ/CTL) of average enrichment values for 9 pairs fell
over a more symmetrical distribution than that of 6 pairs, ranging from .44 to 2.07 with a
median and mean of 1.3 (Sup. Figure 4-3C). Of the 9 pairs enrichment values, 29 had
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Figure 4-3. Enrichment, but not amount, of postsynaptic glutamate receptors and
scaffolding proteins is altered in the LPFC of schizophrenia subjects. Biochemical
fractions enriched for PSDs were prepared from the LPFC of 9 schizophrenic subjects and
matched control and rhesus monkeys treated with different neuroleptics. Quantitative
measures of 107 proteins were aszsayed therein by LC-SRM/MS. Enrichment values for 104
of these proteins were calculated by divideing un-normalized protein measures in PSD
enrichments by un-normalized protein measures in whole cell homogenates. A, shows average
beta tubulin-normalized protein measures from 15 pairs of human tissue. PSD protein levels,
as a group, were not significantly impacted by diagnosis (P = .16), but NR2B did show a trend
upward (P = .07). B, shows average protein enrichment values from 9 pairs of human tissue,
which were significantly increased in PSD preparations from disease tissue, with average
increase of 35% above control (P < .0001). C, shows average beta tubulin-normalized protein
measures from rhesus monkey tissues. PSD protein levels, as a group, were not significantly
impacted by neuroleptic treatment (P = .65), but NR1 was significantly decreased in H Hal (P
= .03). D, shows average protein enrichment values from rhesus monkey tissues, which were
significantly decreased by H Hal (P = .0076). Error bars are standard error of the mean. CTL =
control, SCZ = schizophrenia, Veh = vehicle, and H Hal = high dose haloperidol

elevated enrichment values and 2 had depressed enrichment values with a P < .2 (Sup.
Figure 4-2C & D). Lists of elevated proteins from both data sets include glutamate
receptors, kinases and voltage-dependent anion channels, along with the occasional
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scaffolding protein. Notably, both lists include all AMPA and NR subunits assayed (Sup.
Tables 4-2 A & C). Proteins that were decreased in the 6 pairs included G-protein
subunits (GNB1, GNAs and GNAi1), protein phosphatases (PPP1R7 and PPP2R1A) and
SNARE complex proteins (SYN2, STX1B and STXBP1) (Sup Table 4-2 B). Pathway
analysis in DAVID indicated that the group of proteins with enhanced PSD enrichment in
SCZ patients (in the 9 pair cohort) was enriched for the functional annotation

Figure 4-4. Relative
amounts of PSD proteins
are similar in PSD
enrichments from LPFCs
of control and SCZ
subjects. Biochemical
fractions enriched for PSDs
were prepared from the
LPFC of 9 schizophrenic
subjects and matched
controls and rhesus monkeys
treated with different
neuroleptics and assayed by
LC-SRM/MS. Quantitative
measures of core PSD
proteins were normalized to
PSD95. A, shows average
PSD95-normalized protein
measures from human PSD
enrichments. PSD protein
levels, as a group, were not
significantly impacted by
diagnosis, but SAP97 did
show a trend downward (P =
.08). B, shows average
PSD95-normalized protein
measures from rhesus
monkey PSD enrichments.
The high dose of haloperidol
(H Hal) induced significant
changes to PSD protein
levels (P < .0001). Error bars
are standard error of the
mean. CTL = control, SCZ =
schizophrenia, Veh =
vehicle, and H Hal = high
dose haloperidol
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postsynaptic cell membrane (P = .0007).
Based on the preliminary analysis described above, biochemical enrichment
values for postsynaptic glutamate receptors, scaffolding proteins and voltage-dependent
cation channels were considered as a group. In analyses of both cohorts, diagnosis
significantly impacted protein enrichment values (6 Pairs: P < .0001, 9 Pairs: P = .0003),
all of which were elevated in PSD preparations from SCZ subjects, as compared to
control subjects (Sup. Figure 4-3 D, Figure 4-3 B). Beta tubulin-normalized levels of
these proteins in total homogenates were not significantly increased in SCZ patients in
any of the three batches alone in combinations of batches (Figure 4-3A, 15 pairs),
although NR2B did show a slight increase with and individual P-value of .07.
To determine if neuroleptic treatment could contribute to the observed increase in
PSD protein enrichment, the impact of antipsychotic drug treatment on amount and
enrichment of these PSD proteins in rhesus monkeys was assessed. Glutamate receptor
and scaffolding protein amounts were unaffected by neuroleptics in whole tissue extracts
(clozapine and low haloperidol data not shown; for high haloperidol see Figure 4-3C).
Voltage-dependent cation channel expression was decreased in all three antipsychotic
treatment groups (P = .0005; independent group analysis not shown). In stark contrast to
alterations seen in postmortem tissue of SCZ patients, high dose haloperidol decreased
the enrichment values of 12 out of 15 postsynaptic proteins in PSD preparations (P = <
.0001, Figure 4-3D). Enrichment of VDAC3 was increased while NR2A and GRIM5
were unchanged. Clozapine and low haloperidol treatment did not result in altered
enrichment of these proteins (data not shown).
Enrichment values for five additional manually configured protein groups were
also investigated in PSD preparations from both human and rhesus monkey tissue. No
significant differences were observed between disease and control preparations, while
neuroleptics induced diverse and complicated changes. Enrichment of protein
phosphatases, presynaptic proteins and septins were unchanged, ankyrins and spectrins
were decreased (P = .0004) and neuronal adhesion molecules were increased by low dose
haloperidol, while the high dose haloperidol animals showed either no change or a
possible decrease (Sup. Figure 4-4).
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Finally, PMI and age did not correlate with enrichment values for PSD or SNARE
complex proteins (see supplementary figure 4-6 for representative histograms).
4.3

Relative amounts of core PSD proteins
To compare relative amounts of core PSD proteins in PSD enrichments, protein

measures were normalized to PSD95 measures. No outlying subjects or animals were
identified in this dataset. PSD95-normalized values for postsynaptic glutamate receptors,
scaffolding proteins, kinases and voltage-dependent anion channels were compared in 9
pairs. The relative amounts of these proteins were nearly identical (Figure 4-4A), with the
exception of SAP97, which trended down in the disease group (P = .083). No changes
were seen in the clozapine and low haloperidol groups (data not shown), while high
haloperidol significantly regulated PSD95-normalized values, inducing changes in both
directions between the two groups (P < .0001, Figure 4-4B). PMI and age did not
correlate with PSD95 normalized values of these proteins (Data not shown).
4.4

Unsupervised hierarchical clustering
Unsupervised hierarchical clustering was used to investigate whether relative

protein composition could distinguish between disease and control PSD enrichments.
Clustering analysis was performed using non-normalized values of selected proteins from
6 pairs. The full 9 pairs could not be used, as the clustering analysis was sensitive to the
different enrichment protocols. The analysis returned a striking separation of disease and
control subjects (Figure 4-5A), with only one individual “incorrectly” placed out of each
group. An identical analysis of non-normalized values for the same proteins from whole
cell homogenates was unable to distinguish between disease and control (Figure 4-5B).
Interestingly, the segregation of PSD enrichments into two “correct” groupings appears to
be driven not by core PSD proteins, but by a diverse group of protein phosphates,
presynaptic proteins, GAD65, ankyrins and brain creatine kinase (Sup. Figure 7A). This
constellation of relative changes in SCZ contrasts with clustering of vehicle and high
dose haloperidol samples, in which parsing of animals is driven by relative differences
between the core PSD proteins (Figure 4-5C, Sup Figure 4-7C). Thus, although PSD
enrichments from disease subjects and haloperidol treated animals differ significantly
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from their respective controls, the nature of this dysregulation is fundamentally
dissimilar.
5. Discussion
In this study biochemical fractionation was combined with a quantitative and
targeted proteomics approach to evaluate synaptic protein expression and partitioning in
the LPFC of SCZ. 185 proteins were quantified in whole tissue homogenates prepared
from 15 pairs of SCZ subjects and matched controls. 107 proteins were quantified in PSD
enrichments from 9 pairs. This approach yielded a data set with the statistical power to
make several highly significant observations. The power of this approach also allows for
increased confidence in null results (the finding of few differences in protein expression
between SCZ and controls). Four observations
were made in these experiments: 1) The vast
majority of normalized protein levels was
unaltered in disease tissue, with the exception
of small (20%) but significant increases in
Figure 4-5. Hierarchical clustering separates
subjects by diagnosis based on protein levels
in PSD enrichments but not total
homogenates. A. Unsupervised hierarchical
clustering, with Pearson's Correlation as the
similarity metric, was utilized to group subjects
and selected PSD proteins by non-normalized
protein values measured in PSD enrichments.
SCZ and control were segregated into two groups
with one exception. C = control, S =
schizophrenia. B, shows an identical analysis of
the same subjects and proteins using nonnormalized protein values measured in whole
tissue homogenates. C = control, S =
schizophrenia. C, shows an identical analysis of
the same subjects and proteins using nonnormalized protein values measured in PSD
enrichments from rhesus monkeys. V = vehicle,
HH = high does haloperidol. The open and
closed circles were added to enhance visual
contrast between the two groups in each analysis.
For an expanded version of these heat maps, with
protein annotations, see supplemental Figure 4-7.
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CAMKII and proteolytic pathway proteins (Figure 4-2). 2) PSD glutamate receptors,
scaffolding proteins and voltage-dependent cation channels were, on average, 40% more
enriched in PSD preparations from the tissue of SCZ subjects as compared to control
subjects (Figure 4-3), while the enrichment of ten other proteins group was unaltered. 3)
Despite the enrichment differences, amounts of postsynaptic glutamate receptors,
scaffolding proteins, voltage-dependent cation channels and kinases, normalized to
PSD95, were nearly identical in PSD enrichments from the two groups (Figure 4-4). 4)
The protein composition of PSD enrichments from SCZ samples was sufficiently
different to allow for unsupervised hierarchal clustering to parse disease and control
subjects with striking accuracy, using non-normalized protein values. These four
observations strongly support the conclusion that partitioning, not expression, of PSD
complex proteins is the major molecular correlate of decreased spine density in the LPFC
of SCZ. However, several caveats need to be addressed to increase confidence in these
findings. These caveats are addressed in the next section, before further discussion of the
findings.
5.1

Planned experiments to address experimental caveats

1. Expanding human and rhesus monkey cohorts: Replicating these findings in an
expanded cohort is essential. First, a minimum of 12 additional pairs, prepared in two
batches of 6 using the abridged protocol, will be assayed and the samples from batch 2
removed from future analysis. This will result in a final N of at least 18 per group, with
all samples prepared by an identical protocol. Additionally, the rhesus monkey cohort
generously provided by Dr. Scott Hemby contains 19 more female animals, doubling the
N for all groups. These animals will be prepared and analyzed as well.
2. Increasing options for normalization of protein expression: A constant concern
with any expression study, in regards determining total protein levels in a given
biological sample, is the choice of a loading control. Beta tubulin 3 is often the protein of
choice for normalization in brain tissue. It is often used in protein and mRNA expression
studies in human and animal brain tissue173. Indeed, a recent study of SCZ tissues with
similar cytoarchitectural deficits utilized beta tubulin, concluding that it is unaltered in
disease174. Additionally, multiple proteins and combinations of proteins were evaluated as
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potential normalizing factors post hoc, all of them returning similar results. Indeed,
relative sample-to-sample difference in protein value for the majority of the 185 proteins
quantified mirrored beta tubulin, as is evidenced by the tight distribution of normalized
protein values centered at a median/mean of 1.03 (Figure 4-2A). Finally, within our data
set, there was no protein in the distribution’s higher ranges whose use as a normalizing
factor could be biologically justified. These arguments must be balanced against two
points: 1) Beta tubulin is a major structural component of axons and dendrites and several
groups have reported decreased volume and dendrite length of pyramidal neurons in
additional to spine loss in the DLPFC. Although, these decreases are not as large or
significant as, and do not consistently correlate with, decreased spine density.
Nevertheless, considering decreased neuron volume and dendrite length, decreased
amounts of beta tubulin could mirror decreased pre- and post-synaptic proteins levels, if
present. 2) The list of proteins assayed is, by design, rich in synaptic molecules, limiting
the choices for a non-synaptic normalizer and potentially masking disease effects on the
entire field. To more thoroughly address this potential confound, future analyses will
include peptide SRMs for multiple nuclear, glial and astrocyte markers, even though the
use of these proteins would carry its own caveats. For example, a [synaptic]/[nuclear]
protein normalization would most likely be confounded by projections from other brain
regions. Still, the inspection of this dataset from multiple extra-synaptic normalization
perspectives will likely provide additional valuable information.
3. Additional controls for postmortem interval: The studies modeling postmortem
interval described in Chapter 3 were performed using the full protocol detailed in that
chapter. To thoroughly control for PMI confounds, this experiment will be repeated using
the abridged enrichment protocol used to prepare batch 3.
4. Enrichment variability: Accuracy and precision of the LC-SRM/MS assay was
rigorously validated at several steps in the protocol and validation of the biochemical
fractionation protocol by traditional methods (electron microscopy, Western blot) has
been peer reviewed. However, assessment of fractionation reproducibility from the same
tissue sample by LC-SRM/MS has not been performed. This omission must be addressed,
to complete assessment of method variability at every step of the protocol.
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5. Bioinformatics: The informatics and statistical methods applied here identified protein
groups with expression and enrichment values significantly regulated by diagnosis or
drug treatment. A conservative bar for reaching statistical significance was set to guard
against type I Errors. Due to the testing of multiple hypotheses and dataset complexity,
this analysis should be considered a first step analysis until a more in-depth and rigorous
model can be applied with proper consultation. Ongoing informatics analysis will include
assessment of interactions between proteins across
tissue preparations and in the context of protein
interaction and cellular compartment annotations.
Indeed there are several interesting patterns, discussed
in final Chapter, that hint at deeper findings buried
within this dataset.
5.2

Interpretation of current dataset: A

novel hypothesis for the relationship between
PSD proteins and spine density in
schizophrenia
Decreases in dendritic spine density have been
observed in layers 2 and 3 of the DLPFC in SCZ35, 43.
It logically follows that the levels of proteins that
compose spine PSDs would be decreased as well. The
results of this study, however, are not consistent with
that prediction. Instead, these data suggest that neurons
with decreased spine density, compared to controls,
have the same amounts of PSD proteins, compared to
controls. In this scenario, dendritic spines could contain
more PSD protein, an assertion supported by my data.
PSD enrichments prepared from SCZ subjects were
more enriched for PSD proteins, while the enrichment
of other protein groups was unaltered. Additionally, I
observed that the relative amounts of PSD complex
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Figure 4-6. Possible
configurations of spines and
PSDs in schizophrenia. A,
depicts the “normal”
distribution of PSD complexes
in dendritic spines. B. and C.
show two alternate PSD
complex distributions in which
PSD protein expression is
unaltered and spine density is
decreased in SCZ. B. PSD
protein levels, per spine, are
increased. C. “extra” PSD
complexes are present in
dendritic shafts and are
enriched along with spine
localized PSD complexes in
biochemical preparations.

members are highly similar between SCZ and control subjects. This suggests that while
the amount of PSD complexes at remaining dendrites maybe increased in SCZ, the
relative protein composition of these PSD complexes is unperturbed. Interestingly,
decreased spine density, but increased spine size, has been observed the cortex of
pyramidal neuron NR1 -/- mice 93, suggesting that inhibition of NR function could
increase the amount of PSD proteins at dendritic spines. In an alternate scenario, the
amount of PSD proteins in remaining spines would be unaltered. Instead the “extra” PSD
complexes could exist as lipid rafts175, 176, in the dendritic shaft. These scenarios are
depicted in Figure 4-6. There is however one potential caveat to both of these
interpretations.
While this study has excellent precision and some spatial resolution at the PSD
microdomain, it was still conducted in a whole LPFC section. Thus differences in
synaptic protein expression confined to discreet cortical layers or neuronal subtypes
could still be lost in the complexity of a LPFC homogenate. Given that limitation, the
consistent increased enrichment of all core PSD proteins in SCZ in this tissue implies that
this perturbation is either widespread in the cortex or a large effect confined to a specific
neuronal population.
In addition to the caveats discussed above in section 5.2, three experiments are
essential to flesh out the implications of these findings. 1) Laser capture of discreet
DLPFC cortical layers followed by LC-SRM/MS to quantify layer specific protein levels
would be ideal to confirm or refute the lack of observed differences in protein expression.
The feasibility of this experiment is discussed in Chapter 5. 2) While these findings
suggest that decreased spine density is correlated with increase enrichment of PSD
proteins they do not prove it. Spine density and PSD protein enrichment will need to be
assessed in the same DLPFC tissues of SCZ subjects to determine if such correlation
exists. Encouragingly, a similar experiment, in which decreased spine density was
significantly correlated with decreased septin7 mRNA levels, has been successfully
conducted177. 3) Tissue tomography or electron microscopy, with immuno-gold against
PSD-95, in postmortem tissue will be essential for both confirming that the ratio of PSD
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complexes to spines is increased in SCZ and for determining the location of these
complexes.
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CHAPTER FIVE
CONCLUDING THOUGHTS AND FUTURE
DIRECTIONS
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The goal of this thesis work was to develop a fractionation - mass spectrometry
approach for the quantification of synaptic proteins in human postmortem brain tissue
and apply this approach to the study of synaptic protein expression and PSD partitioning
in the LPFC of SCZ patients. To that end I performed a 2DLC-MS/MS analysis of PSD
enrichments prepared from human postmortem LPFC. The resulting peptide spectral
library, and ones like it, were used to develop an LC-SRM/MS assay for the multiplexed
quantification of peptide SRMs from over 200 synaptic proteins. These peptide SRMs
were rigorously validated for fidelity, accuracy and precision in peptide/protein
quantification. The LC-SRM/MS assay was then used to further validate biochemical
fractionation protocols for the enrichment of synaptic microdomains in human
postmortem brain tissue, demonstrating that subcellular fractions prepared from human
postmortem brain tissue were strikingly similar to those prepared from fresh mouse brain
tissue. Finally, this fractionation – LC-SRM/MS approach was used to quantify close to
200 proteins in whole tissue homogenates prepared from the LPFC of 15 pairs of SCZ
and matched controls subjects and 107 proteins in PSD enrichments prepared from the
LPFC of 9 SCZ and matched control subjects. A preliminary interpretation of the data
from this final experiment strongly suggests that partitioning, not expression, of PSD
proteins is altered in the LPFC of SCZ patients. Based on these results, I have proposed
two possible models to explain how PSD protein expression in the SCZ DLPFC could be
unaltered while dendritic spine density is decreased (Figure 4-6). Additionally, a list of
future experiments is included here, which could be utilized to confirm this finding and
investigate the accuracy of the two proposed models. This work demonstrates the
feasibility and power of combining biochemical methods with a targeted MS proteomics
approach to address a specific question in biology.
As noted previously, comparisons of core PSD proteins, normalized by PSD95,
found PSD complex composition to be highly similar between SCZ and control.
Interestingly, however, when one compares the difference between the average PSD95normalized values for SCZ over control, the size of that difference appears to be related
to the distance between that protein and the PSD in the synapse. That is, the “farther
away” a protein is from the PSD in the synapse, the greater the disparity in that proteins
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PSD95-normalized value between SCZ and control (Figure 5-1). It is possible that this
pattern reflects alterations in the distribution of PSDs throughout the dendrite in SCZ.
Alternatively, these differences could reflect a dysregulation in the interaction between
the PSD and adjacent microdomains.
The findings reported in Chapter 4 dealt almost exclusively with the increased
enrichment of PSD proteins as a group in SCZ. While these findings provide some
insight into
the
distribution
of PSD
complexes in
the dendrites
of SCZ
subjects, they
do not
address
alterations to
PSD
complex
protein
composition
that could
correlate with
NR
hypofunction.
While

Figure 5-1. PSD95 normalized protein values may be related to
postsynaptic density proximity. PSD95 normalized values were
calculated for proteins measured in PSD enrichments from 9 pairs. The
average value for each protein in the SCZ and control groups was taken and
the percent difference ([Control/SCZ)] * 100) between the two groups
calculated for each protein. The percent differences were then given a sign
depending on assumed location in the synapse (- for postsynaptic, + for
presynaptic), plotted in one dimension and color coded by functional.

significant differences between disease and control enrichments were observed in the
PSD95 normalized dataset, the differences in enrichment, discussed in the last paragraph,
must be taken into consideration to interpret these data. The sections below discuss the
next challenges in quantitative proteomics in study of human postmortem brain tissue as
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well as in the interpretation of protein data from synaptic microdomain enrichments.
Selected findings in PSD protein composition and activity will also be presented to
illustrate complications in data interpretation.
1. Proteomics in neuroscience
This study represents a first step towards bringing a targeted proteomic approach to
bear on the study of neuropsychiatric illness in human postmortem brain tissue.
Proteomics investigations can be configured in a variety of ways to achieve numerous
goals. Already, a number of different strategies have been employed to assay
phosphorylation, ubiquitination, nitrosylation and glycosylation events60, 109, 178, 179. In
that vein it is my sincere hope that the neuroscience community here at the University of
Pennsylvania and beyond will utilize and expand upon the method developed as part of
this work to address a variety of questions in the field of neuroscience.
1.1

Layer- or cell type - specific protein quantification in postmortem

studies.
The strategy developed in this thesis has spatial resolution for synaptic microdomains
but not neuronal subtypes or cortical layers. Thus the data generated here allow for the
possibility that PSD protein expression is altered in a specific neuronal population (e.g.
interneurons) or cortical layer; the signal for this alteration lost in the noise of a tissue
homogenate. Furthermore, these data provide little insight into the cell population driving
increased PSD protein enrichment or if these “extra” PSD proteins are localized to
dendrites or elsewhere in the neuron. As previously noted, immunohistochemistry, tissue
tomography and electron microscopy studies will be essential for addressing these
questions. However, these approaches are unable to assay changes to synaptic protein
expression and partitioning in a multiplexed fashion. Thus, adapting the targeted method
developed here to the quantification of protein extracts from specific neuronal
populations or cortical layers is highly desirable. MS proteomics methodologies have
been used to profile proteins in single-cell type populations isolated by flow cytometry180
and laser capture181. Indeed laser capture – proteomics has been used to profile cortical
lewy bodies182 and hippocampal neurofibrillary tangles183 from human postmortem brain
tissue. Laser-capture – qPCR has been utilized to quantify mRNA expression in a
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number of cell
types in human
postmortem
tissues from SCZ
and bipolar
patients107 184 106.
Thus, a lasercapture –
proteomics
approach could be
able to quantify
protein amounts in
discrete cortical
layers.
Figure 5-2. Three different perspectives of PSD protein
composition in schizophrenia. Three different normalizations for
select proteins measured in PSD enrichments from 6 pairs of SCZ and
matched controls. A. shows fold enrichment values, B. protein values
normalized to beta tubulin values and D. protein values normalized to
PSD95. C. LPFC slices from 8 pairs of SCZ and control subjects were
stimulated with 1μM (RS)-2-chloro-5-hydroxyphenylglycine (CHPG).
mGluR5- Gprotein subunit alpha q interaction and mGluR5phosphorylation was quantified by Co-IP and Western blot after
stimulation and at baseline. C, shows the fold induction (stimulated
/baseline) measure for mGluR5 phosphorylation and G-protein
interaction. Note that CHPG induction of phosphorylation, dephosphorylation and G-protein release is attenuated in SCZ tissues,
suggesting that mGluR5 activity is perturbed.

The use of
LC-SRM/MS,
with [13C6]-brain
ISTD, has several
advantages over
LC-MS/MS
strategies. One
advantage is the
low protein

requirement necessary for utilization of this method. The experiments described in
Chapter 4 utilized only 10-20 μg of total protein for preparation, with 10-25% of this
preparation analyzed in one LC-SRM/MS run. In method development experiments
conducted at a ThermoScientific demonstration laboratory (Somerset, NJ) with Dr. Gene
Ciccimaro, we successfully monitored PSD protein peptides, at quantitative intensities, in
as little as 90 ng of peptide injections. An additional benefit of the LC-SRM/MS method
is the [13C6]-brain ISTD which serves as a carrier in addition to its capacity as an internal
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standard. Thus, in a theoretical laser capture experiment, isolated cortical layers could be
collected in a solution containing an excess of the [13C6]-brain ISTD, SDS and reducing
agents. While the optimization and validation of such a protocol would likely be a
significant endeavor, it should be possible utilize LC-SRM/MS with the [13C6]-brain
ISTD for quantification of synaptic proteins in cortical layers isolated by laser capture.
2. Controlling for enrichment confounds in microdomain protein
quantification
Our findings of altered PSD enrichment complicate investigation of the PSD
microdomain in SCZ. Specifically, investigations into altered PSD protein complex
composition must be considered in the context of increased postsynaptic protein
enrichment, lest differences in protein enrichment between SCZ and control tissue be
falsely interpreted as altered trafficking to, or interactions at the PSD. An example is used
to further explain this point:
In Figure 5-2, the levels of six proteins in PSD enrichments from 6 pairs are
considered. The amounts of these proteins, measured in PSD enrichments, are viewed
from three different perspectives: First, as enrichment values (5-2A), next as beta tubulinnormalized protein values (5-2B) and finally as PSD95 normalized-protein values (5-2D).
If these data are viewed from the perspective of beta tubulin (TUBB) normalization,
without taking into account the differences in enrichment, one might conclude that the
amounts of all proteins are increased in the SCZ group. Considering the variations in
enrichment differences between proteins (5-2A), this interpretation would likely be
incorrect. Alternatively, PSD95-normalization (5-2D) likely paints a more accurate
picture of relative protein differences within the PSD complex, but the results must still
be interpreted with caution. PSD95 normalized values for mGluR5 (GRM5) and Gq
alpha (GNAQ) are significantly decreased in PSD enrichments from SCZ subjects (P =
.004 and .03). However, mGluR5 shows the increased enrichment in SCZ shared by the
core PSD proteins PSD95 (DLG4) and GKAP1, while Gq alpha enrichment values
between SCZ and control are highly similar. Thus, one might conclude that the mGluR5
decrease represents dysregulated protein composition “within” the PSD microdomain,
while decreased PSD95-normalized Gq alpha values reflect a fundamental disconnect,
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perhaps in space or in microdomain interaction, between the PSD and its surroundings. It
should be noted that this an example of only 6 out of over 100 proteins, used to illustrate
confounds that should be considered when analyzing quantitative data in a microdomain
enrichment. Going forward a more rigorous statistical consideration of these confounds
must be made.
As a finally note, it should be mentioned that despite the complexities associated
with interpreting this dataset, this example did provide useful information. Both this
experiment and another performed previously on PSD enrichments from a similar cohort
(not discussed here) observed decreased PSD95-normalized mGluR5 levels in PSD
enrichments from SCZ subjects. We hypothesized that this decrease may correlate with
perturbed mGluR5 activity. To investigate this, DLPFC tissue from 8 pairs of SCZ and
matched control tissues were sent to Dr. Hoau-Yan Wang, where ex-vivo stimulation
experiments revealed decreased mGluR5 activity, as measured by receptor
phosphorylation and G alpha q subunit release (Figure 5-2C). This final experiment
demonstrates the promise of the fractionation – LC-SRM/MS approach in assessing
altered protein expression and partitioning events that may be reflective of function
deficits at the synapse in SCZ.
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APPENDIX 1: Supplemental
Tables and Figures
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1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63

Description
Adaptor-related protein complex
ADP-ribosylation factor GTPase-activating protein 1
A-kinase anchor protein 12
A-kinase anchor protein 5
BR serine/threonine protein kinase 1
Brain Creatine Kinase
Calmodulin
Calpain 1
CAMKII Alpha
CAMKII Beta
cAMP-dependent protein kinase/PKA
Cell division protein kinase 5/CDK5
DLG1/SAP97/GKAP
DLG2/PSD-93/Chapsyn-110
DLG4/PSD-95
Dynamin
Glutamate receptor, ionotropic, AMPA 2
Glutamate receptor, ionotropic, AMPA 3
Glutamate receptor, ionotropic, NMDA 2A
Glutamate receptor, ionotropic, NMDA 2B
Glutamate receptor, metabotropic, 5
Gα 13
Gαi 1
Gαi 2
Gαi o
Gαs
Gβ 1
Gβ 2
Gβ 5
Gγ
Heat Shock Protein 70 12A
Homer 1
Inositol 1,4,5 Triphosphate receptor
L-type calcium channel
MAP Kinase
MAP Kinase Kinase
MAP Kinase Kinase Kinase Kinase
nGEF/Neuronal guanine exchange factor
Nitric oxide synthase, brain
Phospholipase A2
PKCα
PKCγ
PKCε
Protein phosphatase 1
Protein phosphatase 2
Protein tyrosine kinase 2B/PYK
Protein tyrosine phosphatase, receptor type D
Protein tyrosine phosphatase, receptor type S
Proto-oncogene tyrosine-protein kinase/Src
Rap guanine nucleotide exchange factor 2/Rap GEF2
Ras GTPase-activating protein/SynGap
Ras-related protein Rab-10
Ras-related protein Rab-3A
Regulator of G-protein singaling 6/RGS 6
Regulator of G-protein singaling 7/RGS 7
Rho GTPase-activating protein/Rho GAP
Rho guanine nucleotide exchange factor/Rho GEF
Rho-Rac guanine nucleotide exchange factor/Rho-Rac GEF
R-type calcium channel
serine threonine kinase DCLK2
SH3 and multiple ankyrin repeat domains protein 3/SHANK3
Voltage-dependent anion-selective channel
Voltage-gated potassium channel

%
Cov
40
29
22
18
15
72
47
20
43
40
41
44
7
13
24
59
11
9
3
6
5
24
20
27
40
12
39
47
19
40
50
21
5
10
21
23
5
12
8
8
28
27
20
23
20
14
8
9
10
12
17
11
12
12
14
11
26
17
4
14
14
21
14

Protein
Probability
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
0.97
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
0.99
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00

IPI
Accession
IPI00619900
IPI00175169
IPI00867627
IPI00307794
IPI00148020
IPI00022977
IPI00075248
IPI00025084
IPI00877169
IPI00334271
IPI00554752
IPI00023530
IPI00552511
IPI00647950
IPI00790650
IPI00887273
IPI00219216
IPI00298700
IPI00029768
IPI00297933
IPI00296244
IPI00290928
IPI00337415
IPI00748145
IPI00398700
IPI00095891
IPI00026268
IPI00003348
IPI00745232
IPI00328128
IPI00011932
IPI00003566
IPI00333753
IPI00219983
IPI00003479
IPI00219604
IPI00219510
IPI00749021
IPI00746356
IPI00220209
IPI00385449
IPI00007128
IPI00024539
IPI00045550
IPI00000030
IPI00029702
IPI00375547
IPI00332271
IPI00641230
IPI00853219
IPI00177884
IPI00016513
IPI00023504
IPI00216329
IPI00220661
IPI00020567
IPI00641543
IPI00291316
IPI00218338
IPI00296360
IPI00847618
IPI00216024
IPI00021088

Table 2-1. Peptide identifications were confirmed by inspection of MS2 spectra and
targeted MS2 analysis of peptide parent masses. Description: IPI identifier. % Cov:
Percent of protein sequence covered by observed peptides.
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Supplemental Figure 2-1. Proteins identified by 2DLC-MS/MS analysis. (A, B and
C) Protein identifications were grouped by GO with respect to Cellular Compartments
(A) Biological Processes (B) and Molecular Functions (C). Each categorization shows
groups of proteins that may be associated with the PSD and the ones that are likely to
be contaminants. (D and E) Protein identifications were compared to the results of
previous studies. (D) Sequences from the 63 confirmed proteins were compared to
those from Trinidad et al. and Dosemeci et al. data sets with the criteria defined as
sequence homology of >90%. (E) Sequences from the 63 confirmed proteins were
compared to those from Trinidad et al. and Dosemeci et al. data sets by identification
based on IPI description; all but 10 were found in one or both data sets.
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Supplemental Figure 3-1. Distribution of Heavy/Light Ratios and Unique Peptide
Pairs. The signal ratio of [13C6]Lysine-Labeled peptides to unlabeled peptides was
calculated. A, shows the distribution of ratios for peptides unique to a single protein
group. B, shows the distribution of Unique [13C6]Lysine-Labeled peptides observed
per protein. C, shows depicts representative chromatographic peaks of light and heavy
peptides from four peptides with different expression values. Note that the y axis is
log10. This figure highlights the similarity in relative protein expression between the
standard and analyte proteomes.

93

Supplemental Figure 3-2. Technical precision of peptide measures. To assess
technical precision in peptide measure, four 30 μg aliquots of a human IM
fraction were individually mixed with 15 μg [13C6]brain ISTD and analyzed by
LC-SRM/MS with triplicate injections. Peptide measure CV was calculated and
the average of these taken for the four repeated preparations. A, shows this
average CV number was plotted against the average integrated area of each
peptide from all preparations and injections. While CV correlates with peak area
(R2 = .71), the CV values but four peptides are under 20%.
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Supplemental
Figure 3-3.
Distribution of
variance in protein
quantification by
fraction. CVs for
protein enrichment
values were
calculated for each
fraction, and the
distribution plotted
in 5 unit bins up to
30%. A, total
homogenate (H). B,
synaptosomal
fraction (SF).C
vesicular (V).D,
papasynaptic
fraction (P).E,
postsynaptic density
(D). The distribution
shape is often
similar between the
two species, but the
center is often lower
in preparations from
mouse tissue.
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Supplemental Figure 3-5. Differences in septin enrichment
are not explained by postmortem interval. We compared
enrichment values for septin proteins in three fractions. A show
enrichment in human parasynaptic fractions (H P) postsynaptic
density (H D) and synaptosomal (H SF). B, shows the same for
fractions prepared from mouse, M P, M D and M SF. C, shows
measures for septin proteins over increasing postmortem interval
(PMI) in D fractions prepared from mouse tissues.
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#
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

Sex
F
F
M
M
F
F
F
F
M
M
M
M
F
F
M
M
F
F
F
F
M
M
F
F
F
F
F
F
F
F

Race
W
W
B
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W

Age
70
76
63
71
85
79
72
77
98
89
86
81
91
96
70
78
92
88
74
76
90
95
72
72
88
77
80
80
81
83

PMI
10.5
9
5
12
11
17
4
11
15
15
7
9
11.5
12.5
19
19
5
7.5
3.5
9.5
6
8.5
7
11.5
7
5.9
15
16
8
7.5

Rx
N
S
N
S
N
S
N
S
N
S
N
S
N
S
N
S
N
S
N
S
N
S
N
S
N
S
N
S
N
S

Batch
1
1
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
3
3

Supplemental Table 4-1. Demographics. # = internal
identification number. Sex, F = female, M = Male.
Race, W = Caucasian, B = African American. Age (y),
PMI = postmortem interval in hours, Rx = diagnosis, N
= normal control, S = schizophrenia. Batch = cohort
the sample was prepared with, see methods.
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Supplemental Figure 4-1. Comparison of enrichment protocols. This figure contrasts
the enrichment values for representative pre- and post- synaptic proteins in PSD
enrichments prepared from the three human and three mice using the method described in
chapter 3, denoted here as “Full” and PSD enrichments prepared from five humans and
five rhesus monkeys using the abridge protocol described in Chapter 4, denoted here as
“Abr”. It is important to know that rhesus monkey brain tissue was dissected from cold
saline profused animals, while tissue from mice was vivisected at body temperature. Thus
differences in enrichment protocol and dissection protocol likely contribute to differences
between these two groups. Fold enrichment values are calculated by dividing the protein
value from the PSD enrichment by protein value from total homogenate. The fold
enrichment of PSD95 (DLG4), CAMK2A and CAMK2A is similar across human and
monkey preparations, while glutamate receptors are more enriched in Abr monkey
compared to Abr human. Presynaptic/SNARE complex proteins are un-enriched by all
proticoals in all animals. While there are differences in enrichment of PSD proteins, likely
owing to PMI confounds in humans, different enrichment protocols and dissection
methods, all four of the preparations were enriched, to some extent, for postsynaptic
glutamate receptors, PSD95 and kinases, excluding presynaptic/SNARE proteins.Human
Full = three human subjects described in Chapter 3, Human Abr = five control subjects
from Chapter 4, batch 3, Monkey Abr = the five vehicle animals described in Chapter 4.
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Supplemental Figure 4-2. Distribution of protein levels and protein enrichment
values.
A. Beta tubulin-normalized protein levels, total homogenate from 15 control subjects.
B. Protein enrichment values, PSD enrichments from 9 control subjects.
C. Protein enrichment values, PSD enrichments from 6 control subjects.
D. Beta tubulin-normalized protein levels, total homogenate from 14 SCZ subjects.
E. Protein enrichment values, PSD enrichments from 8 SCZ subjects.
F. Protein enrichment values, PSD enrichments from 6 SCZ subjects.
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Supplemental Figure 4-3. PSD protein enrichment is elevated in schizophrenia
in both the 9 and 6 pair cohorts. Biochemical fractions enriched for PSDs were
prepared from the LPFC of 9 SCZ subjects and matched controls. Quantitative
measures of 107 proteins were assayed therein by LC-SRM/MS. Enrichment values
for 104 of these proteins were calculated by divideing un-normalized protein
measures in PSD enrichments by un-normalized protein measures in whole cell
homogenates. The average protein enrichment value was taken for each group and the
SCZ average divided by the control average (SCZ/CTL) to obtain a ratio of
dysregulation for each protein. A, shows the distribution of these dysregulation ratios
for 6 pairs. C, shows the distribution of these dysregulation ratios for 9 pairs. B,
shows average protein enrichment values from 6 pairs of human tissue, which were
significantly increased in PSD preparations from disease tissue, (P < .0001). D, shows
average protein enrichment values from 9 pairs of human tissue, which were
significantly increased in PSD preparations from disease tissue, (P < .0001). Note, D.
differs from Figure 4-3B as subject #22, found to be an outlier in the enrichment
dataset, is included here (B. &D.) but not in Figure 4-3B. CTL = control, SCZ =
schizophrenia. Error bars are standard error of the mean.
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Supplemental Tables 4-2. Protein Enrichment differences with a P-value > 2.
A. Proteins with elevated enrichment values in PSD enrichments from 6 pairs.
B. Proteins with decreased enrichment values in PSD enrichments from 6 pairs.
C. Proteins with elevated enrichment values in PSD enrichments from 9 pairs.
D. Proteins with decreased enrichment values in PSD enrichments from 9 pairs.

102

Supplemental Figure 44. Enrichment values
of five functional
protein groups are not
regulated by diagnosis.
Biochemical fractions
enriched for PSDs were
prepared from the LPFC
of 9 schizophrenic
subjects and matched
controls and rhesus
monkeys treated with
different neuroleptics
and fold enrichments
values calculated. These
proteins were manual
sorted into five groups
by function: A. and B,
neuronal cell adhesion,
C. and D, spectrin and
ankrin, E. and F, protein
phosphatases, G. and H,
presynaptic/SNARE
complex, I. and J,
septins. The left column
(A, C, E, G & I) show
enrichment values from
SCZ and control
subjects while the right
column (B, D, F, H & J)
shows values from
rhesus monkey treated
with neuroleptics. CTL
= control subjects, SCZ
= schizophrenia, Veh =
vehicle, Cloz = , L Hal =
low dose haloperidol
and H Hal = high dose
haloperidol. Error bars
are standard error of the
mean.
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Supplemental Figure 4-7. Unsupervised hierarchical clustering, with Pearson's Correlation as the
similarity metric, was utilized to group subjects and selected PSD proteins by non-normalized protein
values measured in PSD enrichments. Subjects with different diagnoses were segregated into two
groups near perfectly. C = control, S = schizophrenia. B, shows an identical analysis of the same
subjects and proteins using non-normalized protein values measured in whole tissue homogenates. C =
control, S = schizophrenia. C, shows an identical analysis of the same subjects and proteins using nonnormalized protein values measured in PSD enrichments from rhesus monkeys. V = vehicle, HH = high
does haloperidol. Proteins are identified by official gene symbol.
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